<!--?xml version="1.0" encoding="UTF-8"?--><doc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" zoom="100" apt_id="1" id="doc_1"><mdata projectname="OUP" category="NARCANCER" apt_id="2" id="mdata_2"><mta name="article-type" apt_id="3" id="mta_3">research-article</mta><mta name="article-subhead" apt_id="4" id="mta_4">Not applicable</mta><mta name="publisher-id" apt_id="5" id="mta_5">zcaf016</mta><mta name="category-oup-series" apt_id="6" id="mta_6">NA</mta><mta name="category-subject-doi" apt_id="7" id="mta_7">NA</mta><mta name="category-taxonomy-collection" apt_id="8" id="mta_8">AcademicSubjects/SCI00030; AcademicSubjects/SCI00980; AcademicSubjects/SCI01060; AcademicSubjects/SCI01140; AcademicSubjects/SCI01180</mta><mta name="category-taxonomy-collection1" apt_id="9" id="mta_9">NA</mta><mta name="doi" apt_id="10" id="mta_10">10.1093/narcan/zcaf016</mta><mta name="supplementary-material-label" id="mta_11" apt_id="11">Graphical Abstract Figure.</mta><mta name="supplementary-material-caption" apt_id="12" id="mta_12">bbbbbbbbbbb</mta><mta name="supplementary-material-graphic" label="image" apt_id="13" id="mta_13">zcaf016_gra.jpg</mta><mta name="pub-date-ppub" apt_id="14" id="mta_14">00-00-2025</mta><mta name="pub-date-epub" apt_id="15" id="mta_15">00-00-2025</mta><mta name="pub-date-collection" apt_id="16" id="mta_16">00-00-2025</mta><mta name="cover-date" apt_id="17" id="mta_17">00-2025</mta><mta name="volume" apt_id="18" id="mta_18">0</mta><mta name="issue" apt_id="19" id="mta_19">0</mta><mta name="fpage" apt_id="20" id="mta_20">1</mta><mta name="lpage" apt_id="21" id="mta_21">0</mta><mta name="elocation-id" apt_id="22" id="mta_22">00</mta><mta name="copyright-statement" apt_id="23" id="mta_23">© The Author(s) 2025. Published by Oxford University Press on behalf of NAR Cancer. <!--?break ?-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</mta><mta name="copyright-year" apt_id="24" id="mta_24">2025</mta><mta name="corrected-typeset" apt_id="25" id="mta_25">DD-MM-YYYY</mta><mta name="meta-name" exinfo="M1" apt_id="26" id="mta_26">edited-state</mta><mta name="meta-value" apt_id="27" id="mta_27">corrected-proof</mta><mta name="meta-name" exinfo="M2" apt_id="28" id="mta_28">article-lifecycle</mta><mta name="meta-value" apt_id="29" id="mta_29">PAP</mta><mta name="self-uri" exinfo="" apt_id="30" id="mta_30">zcaf016.pdf</mta><mta name="feature-fig-label-1" apt_id="31" id="mta_31">NA</mta><mta name="feature-fig-image-1" exinfo="IMG" apt_id="32" id="mta_32">NA</mta><mta name="feature-fig-label-2" apt_id="33" id="mta_33">NA</mta><mta name="feature-fig-image-2" exinfo="IMG" apt_id="34" id="mta_34">NA</mta><mta name="feature-fig-label-3" apt_id="35" id="mta_35">NA</mta><mta name="feature-fig-image-3" exinfo="IMG" apt_id="36" id="mta_36">NA</mta><mta name="source-wc" apt_id="37" id="mta_37">500</mta><mta name="non-printing-chars" apt_id="38" id="mta_38">false</mta><mta name="display-buttons" apt_id="39" id="mta_39">true</mta></mdata><fm apt_id="40" id="fm_40"><lrh title="Left Running Head" apt_id="41" id="lrh_41">Merdler<query><button type="button" title="Copy Editor to Author-AU: CE: Please provide the short title for running head." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="1" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">1</span></button></query>-Rabinowicz <i apt_id="44" id="i_44">et al</i><query><button type="button" title="Copy Editor to Author-AU: CE: Please match the article title with the source file in order to avoid any unnecessary changes at the previous stage. Kindly remove this query post validation." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="2" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">2</span></button></query><i apt_id="47" id="i_47">.</i></lrh><rrh title="Right Running Head" apt_id="48" id="rrh_48"></rrh><dochead title="Doc Head" apt_id="49" id="dochead_49">Standard Article</dochead><ti title="Document Title" apt_id="50" id="ti_50">A Systematic Evaluation of the Therapeutic Potential of Endogenous-ADAR Editors in Cancer Prevention and Treatment<query><button type="button" title="Copy Editor to Author-AU: If your manuscript has figures or text from other sources, please ensure you have permission from the copyright holder. Also ensure that the copyright owner is properly credited, for instance in the figure legends. Make any changes directly in the text. For any questions about permissions, contact jnls.author.support@oup.com." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="3" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">3</span></button></query><query><button type="button" title="Copy Editor to Author-AU: CE: It is mandatory to insert a query for the author if any grammatical and stylistic changes are made in the title of the paper. Please insert an author query for the changes made in the title." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="4" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">4</span></button></query> </ti><aug title="Authors" sep=", " lsep="" apt_id="55" id="aug_55"><au suffix="1,2,3,†" rid="87 97 104 126" orcid="https://orcid.org/0000-0002-6133-8158" apt_id="56" id="au_56"><f title="First name" apt_id="57" id="f_57">Rona</f><s title="Surname" apt_id="58" id="s_58">Merdler-Rabinowicz</s></au><au suffix="2,3,†" rid="97 104 126" apt_id="59" id="au_59"><f title="First name" apt_id="60" id="f_60">Ariel</f><s title="Surname" apt_id="61" id="s_61">Dadush</s></au><au suffix="1" rid="87" apt_id="62" id="au_62"><f title="First name" apt_id="63" id="f_63">Sumeet</f><s title="Surname" apt_id="64" id="s_64">Patiyal</s></au><au suffix="1" rid="87" apt_id="65" id="au_65"><f title="First name" apt_id="66" id="f_66">Padma Sheila</f><s title="Surname" apt_id="67" id="s_67">Rajagopal</s></au><au suffix="1" rid="87" apt_id="68" id="au_68"><f title="First name" apt_id="69" id="f_69">Gulzar N.</f><s title="Surname" apt_id="70" id="s_70">Daya</s></au><au suffix="2" rid="97" orcid="https://orcid.org/0000-0002-6425-4259" apt_id="71" id="au_71"><f title="First name" apt_id="72" id="f_72">Shay</f><s title="Surname" apt_id="73" id="s_73">Ben-Aroya</s></au><au suffix="1" rid="87" apt_id="74" id="au_74"><f title="First name" apt_id="75" id="f_75">Alejandro A.</f><s title="Surname" apt_id="76" id="s_76">Schäffer</s></au><au suffix="4" rid="111" orcid="https://orcid.org/0000-0001-8681-3202" apt_id="77" id="au_77"><f title="First name" apt_id="78" id="f_78">Eli</f><s title="Surname" apt_id="79" id="s_79">Eisenberg</s></au><au suffix="1,†" rid="87 126" orcid="https://orcid.org/0000-0002-3390-110X" apt_id="80" id="au_80"><f title="First name" apt_id="81" id="f_81">Eytan</f><s title="Surname" apt_id="82" id="s_82">Ruppin</s></au><au suffix="2,3,*,†" rid="97 104 119 126" orcid="https://orcid.org/0000-0002-3641-4198" apt_id="83" id="au_83"><f title="First name" apt_id="84" id="f_84">Erez Y.</f><s title="Surname" apt_id="85" id="s_85">Levanon</s></au></aug><affg type="arabic" apt_id="86" id="affg_86"><aff id="aff_87" sno="1" type="arabic" apt_id="87">Cancer Data Science Lab, <org title="Organization" apt_id="88" id="org_88">Center for Cancer Research, National Cancer Institute, National Institutes of Health</org>, <str title="Street" apt_id="89" id="str_89">Bethesda</str>, MD, <cny title="Country" apt_id="90" id="cny_90">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide institute/postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="5" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">5</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please provide department for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="6" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">6</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please check the spelling and accuracy of all author names and affiliations, particularly for any co-authors. Also check that author surnames are correctly highlighted. This is to ensure that forenames and surnames are tagged correctly for online indexing. Incorrect names and affiliations may lead to an author not being credited for their work by funders, institutions, or other third parties. Make any changes directly in the text. Note that changes to your authorship list (adding or removing authors, changing designation of corresponding author) require additional approvals. Email jnls.author.support@oup.com if this is required." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="7" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">7</span></button></query></aff><aff id="aff_97" sno="2" type="arabic" apt_id="97"><org title="Organization" apt_id="98" id="org_98">Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University</org>, Ramat Gan, <cny title="Country" apt_id="99" id="cny_99">Israel</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="8" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">8</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please provide department for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="9" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">9</span></button></query></aff><aff id="aff_104" sno="3" type="arabic" apt_id="104"><org title="Organization" apt_id="105" id="org_105">The Institute of Nanotechnology and Advanced Materials, Bar‐Ilan University</org>, Ramat Gan, <cny title="Country" apt_id="106" id="cny_106">Israel</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="10" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">10</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please provide department for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="11" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">11</span></button></query></aff><aff id="aff_111" sno="4" type="arabic" apt_id="111"><org title="Organization" apt_id="112" id="org_112">Raymond and Beverly Sackler School of Physics and Astronomy, Tel-Aviv University</org>, Tel Aviv, <cny title="Country" apt_id="113" id="cny_113">Israel</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="12" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">12</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please provide department for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="13" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">13</span></button></query></aff></affg><coraddg type="symbol" apt_id="118" id="coraddg_118"><coradd title="Cor Address" id="coradd_119" sno="*" type="symbol" apt_id="119">To whom correspondence should be addressed. Erez Y. Levanon. Email: <email href="mailto:Erez.Levanon@biu.ac.il" title="e-Mail" apt_id="120" id="email_120">Erez.Levanon@biu.ac.il</email><query><button type="button" title="Copy Editor to Author-AU: CE: phone is missing, please provide." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="14" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">14</span></button></query><query><button type="button" title="Copy Editor to Author-AU: CE: Fax is missing, please provide." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="15" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">15</span></button></query></coradd></coraddg><noteg type="symbol" apt_id="125" id="noteg_125"><note type="symbol" id="note_126" sno="†" apt_id="126">Equal contribution.</note></noteg><hsy title="History" sep=";" id="hsy_127" apt_id="127"><re apt_id="128" id="re_128">December 10, 2024</re><rsd apt_id="129" id="rsd_129">March 10, 2025</rsd><edd apt_id="130" id="edd_130">April 8, 2025</edd></hsy><absg apt_id="131" id="absg_131"><ti title="Abstract Head" apt_id="132" id="ti_132">Abstract</ti>
<p t="fl" title="Paragraph No Indent" apt_id="133" id="p_133">Adenosine deaminases acting on RNA (ADAR) enzymes constitute a natural cellular mechanism that induces A-to-I(G) editing, introducing genetic changes at the RNA level. Recently, interest in the endogenous-ADAR editor has emerged for correcting genetic mutations, consisting of a programmed oligonucleotide that attracts the native ADAR, thereby offering opportunities for medical therapy. Here, we systematically chart the scope of cancer mutations that endogenous-ADAR can correct. First, analyzing germline single nucleotide variants in cancer predisposition genes, we find that endogenous-ADAR can revert a fifth of them, reducing the risk of cancer development later in life. Second, examining somatic mutations across various cancer types, we find that it has the potential to correct at least one driver mutation in over a third of the samples, suggesting a promising future treatment strategy. We also highlight key driver mutations that are amenable to endogenous-ADAR, and are thus of special cinical interest.</p>
<p t="fl" title="Paragraph No Indent" apt_id="134" id="p_134">As using endogenous-ADAR entails delivering relatively small payloads, the prospects of delivering endogenous-ADAR to various cancers seem promising. We expect that the large scope of correctable mutations that are systematically charted here for the first time will pave the way for a new era of cancer treatment options<query><button type="button" title="Copy Editor to Author-AU: The abstract has been edited as a single paragraph to match journal style. Please edit, if necessary, directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="16" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">16</span></button></query>.<query><button type="button" title="Copy Editor to Author-AU: Please provide a short caption for the graphical abstract." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="17" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">17</span></button></query></p>
</absg><absg exinfo="graphical" apt_id="139" id="absg_139"><ti title="Abstract Head" apt_id="140" id="ti_140">Graphical Abstract</ti><fig id="fig_141" apt_id="141"><ti title="Abstract Head" apt_id="142" id="ti_142">aaaaaaaaa</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_gra.jpg" title="Figure" apt_id="143" id="img_143" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="144" id="button_144"><i class="fa-solid fa-pen-to-square" apt_id="145" id="i_145"></i></button></fig> </absg></fm><bdy apt_id="146" id="bdy_146"><sect1 id="sect1_147" sec-type="intro" apt_id="147"><ti title="Heading 1" apt_id="148" id="ti_148">Introduction</ti>
<p t="fl" title="Paragraph No Indent" apt_id="149" id="p_149">Base editing is an arsenal of techniques that enable the precise manipulation of the genome sequence by efficiently converting nucleotides. Initially explored for inherited diseases, base editing holds the potential to address various genetically driven disorders, as many inherited diseases arise from single pathogenic point mutations involving altered nucleotides, referred to as single nucleotide variants (SNVs) [<bibcit rid="524" title="bibcit" href="#" contenteditable="false" id="bibcit_150" sno="1" apt_id="150">1</bibcit>, <bibcit rid="542" title="bibcit" href="#" contenteditable="false" id="bibcit_151" sno="2" apt_id="151">2</bibcit>]. In the context of cancer, the high mutational burden of tumors may appear to constrain the efficacy of such techniques. Yet, we propose that a novel technology utilizing endogenous RNA-editing enzymes [<bibcit rid="561" title="bibcit" href="#" contenteditable="false" id="bibcit_152" sno="3" apt_id="152">3</bibcit>] may prove beneficial.</p>
<p t="i" title="Paragraph Indented" apt_id="153" id="p_153">Ongoing investigations have shown promising initial outcomes for several common genetic diseases [<bibcit rid="579" title="bibcit" href="#" contenteditable="false" id="bibcit_154" sno="4" apt_id="154">4</bibcit>]. The leading breakthrough demonstrated the restoration of the common <i apt_id="155" id="i_155">SERPINA1</i> variant, which causes the genetic disease alpha-1-antitrypsin deficiency, in non-human primates [<bibcit rid="597" title="bibcit" href="#" contenteditable="false" id="bibcit_156" sno="5" apt_id="156">5</bibcit>]. Following this success, the public company Wave Life Sciences has announced the first-ever worldwide dosing of two patients with this variant.</p>
<p t="i" title="Paragraph Indented" apt_id="157" id="p_157">In addition to reverting common pathogenic variants, the precise programmability for specific sequences facilitates customization for rare genetic variants [<bibcit rid="615" title="bibcit" href="#" contenteditable="false" id="bibcit_158" sno="6" apt_id="158">6</bibcit>], tailoring them to individual patients within affordability and delivery constraints. This substantially broadens the applicability of endogenous RNA editing to address a wide range of genetic abnormalities. Here we suggest that by targeting critical variants – germline predisposing mutations or somatic driver mutations – there is potential to exert a substantial impact in cancer. A compelling study was recently conducted in glioblastoma, wherein selective editing of the mutant <i apt_id="159" id="i_159">TERT</i> promoter using a DNA base editor led to pre-clinical benefit [<bibcit rid="633" title="bibcit" href="#" contenteditable="false" id="bibcit_160" sno="7" apt_id="160">7</bibcit>]. While the technology used in this case was not RNA editing, the study still gives hope for the potential of RNA editing.</p>
<p t="i" title="Paragraph Indented" apt_id="161" id="p_161">The core of programmable RNA editing revolves around the design of a guide RNA (gRNA). The gRNA ensures target specificity through Watson-Crick base pairing to the desired region and also harnesses the native adenosine deaminases acting on RNA (ADAR), which is responsible for the extensive metazoan A-to-I editing [<bibcit rid="651" title="bibcit" href="#" contenteditable="false" id="bibcit_162" sno="8" apt_id="162">8</bibcit>], that is then read as G by the cellular machineries [<bibcit rid="669" title="bibcit" href="#" contenteditable="false" id="bibcit_163" sno="9" apt_id="163">9</bibcit>, <bibcit rid="686" title="bibcit" href="#" contenteditable="false" id="bibcit_164" sno="10" apt_id="164">10</bibcit>]. As ADAR is naturally expressed at high levels in all body tissues, either the cytoplasmic isoform p150 or the nuclear isoform p110 [<bibcit rid="704" title="bibcit" href="#" contenteditable="false" id="bibcit_165" sno="11" apt_id="165">11</bibcit>], this method offers the advantage of a small molecular payload, in contrast to other base-editing methods. Delivering only the programmed chemically modified oligonucleotide to any target cell eliminates the need for an external viral vector or plasmid to insert the enzyme [<bibcit rid="718" title="bibcit" href="#" contenteditable="false" id="bibcit_166" sno="12" apt_id="166">12</bibcit>], thereby also reducing the immunogenic response to foreign components. Recent studies indicate that a guide consisting of merely 30–40 nucleotides can be sufficient, making this approach highly appealing [<bibcit rid="597" title="bibcit" href="#" contenteditable="false" id="bibcit_167" sno="5" apt_id="167">5</bibcit>, <bibcit rid="736" title="bibcit" href="#" contenteditable="false" id="bibcit_168" sno="13" apt_id="168">13</bibcit>].</p>
<p t="i" title="Paragraph Indented" apt_id="169" id="p_169">Unlike other base editors that can be tailored to target either a DNA sequence or an RNA sequence [<bibcit rid="754" title="bibcit" href="#" contenteditable="false" id="bibcit_170" sno="14" apt_id="170">14</bibcit>, <bibcit rid="768" title="bibcit" href="#" contenteditable="false" id="bibcit_171" sno="15" apt_id="171">15</bibcit>], endogenous-ADAR is capable of changing only RNA sequences [<bibcit rid="561" title="bibcit" href="#" contenteditable="false" id="bibcit_172" sno="3" apt_id="172">3</bibcit>, <bibcit rid="786" title="bibcit" href="#" contenteditable="false" id="bibcit_173" sno="16" apt_id="173">16</bibcit>]. The RNA-ony limitation can be viewed as more cautious than DNA editing because editing the DNA sequence involves the risk of introducing irreversible errors into the DNA. Such errors may result from gRNA binding to undesired regions, leading to the unintentional conversion of distant nucleotides (off-target sites), or when the gRNA is correctly bound but the enzyme edits additional nucleotides in the vicinity of the targeted nucleotide (bystander edits) [<bibcit rid="800" title="bibcit" href="#" contenteditable="false" id="bibcit_174" sno="17" apt_id="174">17</bibcit>]. In contrast, targeting the RNA is considered safer, given that RNA molecules are constantly synthesized and degraded within cells [<bibcit rid="814" title="bibcit" href="#" contenteditable="false" id="bibcit_175" sno="18" apt_id="175">18</bibcit>]. The drawback of RNA editing is that this approach requires continuous and prolonged treatment, posing challenges for patients in adherence and feasibility. In addition, CRISPR-guided base editors were found to induce transcriptome-wide RNA errors [<bibcit rid="831" title="bibcit" href="#" contenteditable="false" id="bibcit_176" sno="19" apt_id="176">19</bibcit>, <bibcit rid="849" title="bibcit" href="#" contenteditable="false" id="bibcit_177" sno="20" apt_id="177">20</bibcit>], including posing carcinogenic effects on cells [<bibcit rid="867" title="bibcit" href="#" contenteditable="false" id="bibcit_178" sno="21" apt_id="178">21</bibcit>, <bibcit rid="886" title="bibcit" href="#" contenteditable="false" id="bibcit_179" sno="22" apt_id="179">22</bibcit>]. Another distinction lies in the spectrum of editable variants, as endogenous-ADAR operates exclusively on G &gt; A variants at the RNA level. Yet, it is worth noting that because RNA editing may occur before splicing, it has the flexibility to target all gene regions, encompassing introns, excluding promoters. Since most RNA editing occurs shortly after transcription [<bibcit rid="904" title="bibcit" href="#" contenteditable="false" id="bibcit_180" sno="23" apt_id="180">23</bibcit>], it could correct potentially harmful variants before the nonsense-mediated decay (NMD) cellular mechanism is triggered. In fact, since gene expression and RNA editing are not directly correlated, RNA editing can effectively target the majority of variant types, with the exception of variants located in promoters that result in silent expression, which are relatively rare.</p>
<p t="i" title="Paragraph Indented" apt_id="181" id="p_181">In the context of cancer, endogenous-ADAR present an additional noteworthy advantage; Expression levels of the natural ADAR enzymes (both ADAR1 and ADAR2) are rather high in most cancer types and the expression levels of the main editing enzyme, ADAR1, is known to be elevated in most cancer types [<bibcit rid="922" title="bibcit" href="#" contenteditable="false" id="bibcit_182" sno="24" apt_id="182">24</bibcit>], which may contribute to the efficacy of the treatment, as well as an increased selectivity to cancer versus non cancer cells.</p>
<p t="i" title="Paragraph Indented" apt_id="183" id="p_183">Here, our objective is to explore systematically the potential of endogenous-ADAR for cancer prevention and treatment, considering its unique advantages and straightforward design for therapy. The first approach we explore focuses on cancer risk reduction/prevention, leveraging the existing application of endogenous-ADAR to genetic diseases. Inherited variants in cancer predisposition genes do not necessarily lead to cancer in infancy but rather are associated with increased lifetime risks of developing cancers [<bibcit rid="940" title="bibcit" href="#" contenteditable="false" id="bibcit_184" sno="25" apt_id="184">25</bibcit>]. Correcting these variants before cancer initiation holds the potential for preventive intervention. The second approach explores potential avenues for cancer treatment, utilizing endogenous-ADAR to correct driver mutations essential for tumor development and progression. We hypothesize that since only a small subset of the tumor's mutations are considered drivers, directing the therapy toward key driver variants, central to cancer initiation and progression, holds the potential to improve a patient's trajectory. This reasoning is in line with current precision oncology therapies that mostly target a single mutation driver genes.</p>
<p t="i" title="Paragraph Indented" apt_id="185" id="p_185">To evaluate the feasibility of this approach, we map the landscape of inherited cancer predisposition mutations and driver mutations that can be corrected via endogenous-ADAR across multiple cancer types. Leveraging endogenous-ADAR in this manner may introduce a new and powerful weapon to the arsenal of precision medicine techniques.</p>
</sect1><sect1 id="sect1_186" sec-type="methods" apt_id="186"><ti title="Heading 1" apt_id="187" id="ti_187">Methods</ti><sect2 id="sect2_188" apt_id="188"><ti title="Heading 2" apt_id="189" id="ti_189">Germline mutation data</ti>
<p t="fl" title="Paragraph No Indent" apt_id="190" id="p_190">We obtained (a snapshot of) the ClinVar database [<bibcit rid="954" title="bibcit" href="#" contenteditable="false" id="bibcit_191" sno="26" apt_id="191">26</bibcit>] from the UCSC Browser on 08-Nov-2021. At that time, the database contained 1 103 629 mutations, with 984 981 being SNVs. We excluded 147 genetic downstream and 1067 genetic upstream transcript variants, 237 mutations with no sequence alteration, 77 091 that had no molecular consequence information, 391 mutations that were mistakenly classified as SNVs and 2 052 mitochondrial mutations. This left us with 973 996 SNVs located in genes. Next, we filtered the 98 513 SNVs that were reported to be clinically pathogenic. We considered any phrase containing derivatives of the word “pathogenic” (e.g. “pathogenic”, “likely pathogenic”) to include these variants. In cases where there were conflicting interpretations of pathogenicity, we included the variant if at least one submitter reported it as pathogenic according to the ClinVar VCF file. We used the isoform “MANE SELECT” as presented in ClinVar and the reported coordinates (column OrigName) of each variant, to extract the RNA sequence from the CDS FASTA file that was downloaded from the UCSC genome browser (<url title="URL" type="uri" href="http://genome.ucsc.edu" apt_id="192" id="url_192">http://genome.ucsc.edu</url>) [<bibcit rid="972" title="bibcit" href="#" contenteditable="false" id="bibcit_193" sno="27" apt_id="193">27</bibcit>] on 27-Mar-2022, as well as the reading frame of each variant (i.e. the 3-nucleotide codon sequence).</p>
<p t="i" title="Paragraph Indented" apt_id="194" id="p_194">We utilized the 64 CPGs used in a test by PreventionGenetics and described in the Genetic Test Registry (GTR) curated by NCBI [<bibcit rid="990" title="bibcit" href="#" contenteditable="false" id="bibcit_195" sno="28" apt_id="195">28</bibcit>]. Out of the 98 513 SNVs examined, 8 251 were found in these specified genes. We further filtered the variants, focusing only on those classified as causing Hereditary cancer-predisposing syndrome based on the classification provided by MedGen [<bibcit rid="997" title="bibcit" href="#" contenteditable="false" id="bibcit_196" sno="29" apt_id="196">29</bibcit>] (MedGen UID: 14 326, Concept ID: C0027672, Neoplastic Process). In total, our analysis included 2 820 human pathogenic SNVs known to be associated with hereditary cancer syndromes and conditions in 40 different genes. For each variant, we extracted the DNA sequence using Bedtool getfasta (hg38 reference human genome).</p>
<p t="i" title="Paragraph Indented" apt_id="197" id="p_197">In the second analysis, we used data curated by Srinivasan <i apt_id="198" id="i_198">et al.</i> [<bibcit rid="1004" title="bibcit" href="#" contenteditable="false" id="bibcit_199" sno="30" apt_id="199">30</bibcit>], a study that investigated the context-specific role of germline pathogenicity in tumorigenesis from the MSK-IMPACT cohort of 17 152 adult patients with cancer who underwent prospective sequencing. To obtain the relevant data, we accessed their SignalDB website [<bibcit rid="1004" title="bibcit" href="#" contenteditable="false" id="bibcit_200" sno="30" apt_id="200">30</bibcit>] and manually extracted the 450 high-penetrance germline mutations. In selecting only SNVs, this number was reduced to 248. In 9 cases, the cancer type was not specified, resulting in a final set of 239 SNVs that were included in our analysis.</p>
<p t="i" title="Paragraph Indented" apt_id="201" id="p_201">For the off-target analysis we utilized the BLAT [<bibcit rid="1022" title="bibcit" href="#" contenteditable="false" id="bibcit_202" sno="31" apt_id="202">31</bibcit>] program, searching for areas in the human genome that displayed substantial similarity to the 40 bases surrounding each variant. Different RNA editing methods use different lengths but the region that complements the guide is typically at most 40 nucleotides. We employed cautious parameters of 85% identity (varying this parameter from 75% to 95% did not have any discernible impact on the results) and a minimum alignment length of 20 nucleotides. For the bystander analysis, we examined the 20 bases surrounding each variant using the AlphaMissense prediction model [<bibcit rid="1032" title="bibcit" href="#" contenteditable="false" id="bibcit_203" sno="32" apt_id="203">32</bibcit>], which evaluates the impact of all possible nucleotide changes on protein function. Changes that were defined by the model as “Pathogenic” or “Likely pathogenic” were counted. We utilized either the hg19 or hg38 version of the model, depending on the variant database under investigation.</p>
</sect2><sect2 id="sect2_204" apt_id="204"><ti title="Heading 2" apt_id="205" id="ti_205">Driver mutations analysis</ti>
<p t="fl" title="Paragraph No Indent" apt_id="206" id="p_206">To evaluate the potential of endogenous-ADAR in reverting driver mutations, we acquired publicly available and controlled data from the PCAWG project on 03-May-2023. The dataset comprised 5 788 driver mutations identified in 2 010 patients across 36 distinct cancer types.</p>
<p t="i" title="Paragraph Indented" apt_id="207" id="p_207">To compute the proportions of endogenous-ADAR targetable variants, we divided the number of editable variants by the total number of mutations in each specific cancer type. To determine the statistical significance of the editable proportions in each cancer type compared to the others, we employed the non-parametric Mann-Whitney U test, also known as the Mann-Whitney-Wilcoxon test. Additionally, we applied FDR multiple-testing correction to account for multiple comparisons and evaluate the statistical differences between the groups.</p>
<p t="i" title="Paragraph Indented" apt_id="208" id="p_208">To determine the cumulative percentage of cells undergoing editing, we employed these probability equations when a single driver mutation edit is sufficient (<latex src="https://pxeqa.aptaracorp.com/ED6010/home/zcaf016_peqn_2054026772.gif" id="latex_209" apt_id="209"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_peqn_2054026772.gif" apt_id="210" id="img_210" /><!--<?TeX $N$?>--></latex> is the number of driver mutations, <latex src="https://pxeqa.aptaracorp.com/ED6010/home/zcaf016_peqn_1702654881.gif" id="latex_211" apt_id="211"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_peqn_1702654881.gif" apt_id="212" id="img_212" /><!--<?TeX $X$?>--></latex> is the probability of correcting one mutation in a given cell, <latex src="https://pxeqa.aptaracorp.com/ED6010/home/zcaf016_peqn_325699162.gif" id="latex_213" apt_id="213"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_peqn_325699162.gif" apt_id="214" id="img_214" /><!--<?TeX $Y$?>--></latex> is the probability to correct at least <latex src="https://pxeqa.aptaracorp.com/ED6010/home/zcaf016_peqn_744855199.gif" id="latex_215" apt_id="215"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_peqn_744855199.gif" apt_id="216" id="img_216" /><!--<?TeX $N$?>--></latex> mutations):</p>
<eqn sub-type="" id="eqn_217" apt_id="217"><latex src="https://pxeqa.aptaracorp.com/ED6010/home/zcaf016_peqn_138427408.gif" apt_id="218" id="latex_218"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_peqn_138427408.gif" apt_id="219" id="img_219" /><!--<?TeX \begin{equation*}\begin{array}{@{}*{2}{c}@{}} {N = 1}&{\ Y = X}\\ {N = 2}&{Y = 1 - {{{\left( {1 - X} \right)}}^2}}\\ {N = 3}&{Y = 1 - {{{\left( {1 - X} \right)}}^3}} \end{array},\end{equation*}?>--></latex></eqn>
<p t="cont" title="Paragraph Continue" apt_id="220" id="p_220">and when two driver mutations edits are required:</p>
<eqn sub-type="" id="eqn_221" apt_id="221"><latex src="https://pxeqa.aptaracorp.com/ED6010/home/zcaf016_peqn_1934539164.gif" apt_id="222" id="latex_222"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_peqn_1934539164.gif" apt_id="223" id="img_223" /><!--<?TeX \begin{equation*}\begin{array}{@{}*{2}{c}@{}} {N = 1}&{Y = 0}\\ {N = 2}&{Y = {{X}^2}}\\ {\begin{array}{@{}*{1}{c}@{}} {N = 3}\\ {N = 4} \end{array}}&{\begin{array}{@{}*{1}{c}@{}} {Y = 3{{{\rm{X}}}^2}\left( {1 - {\rm{X}}} \right) + {{{\rm{X}}}^3}}\\ {{\rm{Y}} = 6{{{\rm{X}}}^2}{{{\left( {1 - {\rm{X}}} \right)}}^2} + 4{{{\rm{X}}}^3}\left( {1 - {\rm{X}}} \right) + {{{\rm{X}}}^4}} \end{array}} \end{array}\end{equation*}?>--></latex></eqn></sect2></sect1><sect1 id="sect1_224" sec-type="results" apt_id="224"><ti title="Heading 1" apt_id="225" id="ti_225">Results</ti><sect2 id="sect2_226" apt_id="226"><ti title="Heading 2" apt_id="227" id="ti_227">Overview</ti>
<p t="fl" title="Paragraph No Indent" apt_id="228" id="p_228">First, we focus on variants within established pediatric cancer predisposition genes to demonstrate the potential of reverting germline mutations, as correcting them offers the most direct potential benefit. Additionally, we examine pathogenic germline mutations associated with high penetrance cancer predisposition in adults. For each variant correctable by endogenous-ADAR we further investigate the likelihood of distant off-target sites and pathogenic bystander edits.</p>
<p t="i" title="Paragraph Indented" apt_id="229" id="p_229">In the second approach, aimed at showcasing the potential of reverting somatic driver mutations, we analyze a database of oncologic patients across various cancer types, where driver mutations were reported for each individual. We evaluate the potential for addressing each driver mutation using endogenous-ADAR, which involves assessing the likelihood of off-target and bystander edits. Samples and different cancer types are ranked by potential for editability.</p>
</sect2><sect2 id="sect2_230" apt_id="230"><ti title="Heading 2" apt_id="231" id="ti_231">Targeting cancer predisposition germline mutations</ti>
<p t="fl" title="Paragraph No Indent" apt_id="232" id="p_232">To assess the potential of endogenous-ADAR in targeting pathogenic germline mutations in cancer predisposition genes (CPGs), we implemented the following pipeline: We curated a set of 64 CPGs that are widely used in a test by PreventionGenetics for pediatric genetic testing due to their association with different genetic cancer clinical conditions [<bibcit rid="990" title="bibcit" href="#" contenteditable="false" id="bibcit_233" sno="28" apt_id="233">28</bibcit>] (<url title="URL" type="uri" href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcaf016#supplementary-data" apt_id="234" id="url_234">Supplementary Table S1</url>). We then extracted all pathogenic variants (Methods) in these genes from ClinVar [<bibcit rid="954" title="bibcit" href="#" contenteditable="false" id="bibcit_235" sno="26" apt_id="235">26</bibcit>], and kept those classified as causing a “Neoplastic Syndrome” based on the classification provided by MedGen [<bibcit rid="997" title="bibcit" href="#" contenteditable="false" id="bibcit_236" sno="29" apt_id="236">29</bibcit>]. Our analysis ultimately included 2 820 human pathogenic SNVs predicted to be associated with inherited pediatric cancer risk syndromes. Out of the 2 820 curated SNVs, 566 (20%) were G &gt; A variants, which are suitable targets for endogenous-ADAR (Fig. <figcit rid="238" title="figcit" href="#" contenteditable="false" id="figcit_237" sno="1" apt_id="237">1</figcit>a). The G &gt; A mismatch type occurs more frequently than expected because transition variants are more common than transversion variants, and the most frequent mismatch—C &gt; T—results in a G &gt; A conversion on the complementary DNA strand. Consequently, the prevalence of G &gt; A pathogenic variants is notably higher than average.</p>
<fig id="fig_238" prefix="Figure" suffix="." sno="1" type="arabic" sub-type="" apt_id="238"><ti title="Figure Caption" prefix="Figure" suffix="." sno="1" type="arabic" sub-type="" apt_id="239" id="ti_239">Distribution of targetable pathogenic germline mutations. a. Distribution of established pathogenic germline mutations, categorized by cancer predisposition genes: A total of 2 820 SNVs linked to hereditary pediatric cancer risk syndromes are presented based on the respective genes. in parentheses: the total count of variants identified for each gene; in pink: SNVs suitable for endogenous-ADAR; in black: SNVs not suitable for endogenous-ADAR. b: Distribution of high-penetrance pathogenic germline mutations: A total of 239 germline SNVs obtained from the Memorial Sloan Kettering's SIGNAL database, originating from sequencing of adult cancer patients, are presented by cancer subtype and gene. in pink: SNVs suitable for endogenous-ADAR; in black: SNVs not suitable for endogenous-ADAR<query><button type="button" title="Copy Editor to Author-AU: Figures have been edited to conform to journal style. Please check all figures carefully. If any adjustments are needed, where possible please note these as instructions to the typesetter rather than providing a replacement figure." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="18" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">18</span></button></query>.</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_f1.jpg" title="Figure" apt_id="242" id="img_242" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="243" id="button_243"><i class="fa-solid fa-pen-to-square" apt_id="244" id="i_244"></i></button></fig></sect2><sect2 id="sect2_245" apt_id="245"><ti title="Heading 2" apt_id="246" id="ti_246">The risk of off-target effects and bystander edits is low</ti>
<p t="fl" title="Paragraph No Indent" apt_id="247" id="p_247">For precise on-target editing, meticulous gRNA design is essential to ensure binding to the targeted region and minimize the risk of off-target effects. This constraint limits the applicability in regions that exhibit high similarity to other genomic regions.</p>
<p t="i" title="Paragraph Indented" apt_id="248" id="p_248">To identify potential off-target effects, we searched for areas in the human genome that displayed substantial similarity to the 40 bases surrounding each variant (Methods), based on recent reports [<bibcit rid="736" title="bibcit" href="#" contenteditable="false" id="bibcit_249" sno="13" apt_id="249">13</bibcit>, <bibcit rid="1051" title="bibcit" href="#" contenteditable="false" id="bibcit_250" sno="33" apt_id="250">33</bibcit>, <bibcit rid="1069" title="bibcit" href="#" contenteditable="false" id="bibcit_251" sno="34" apt_id="251">34</bibcit>] highlighting the optimal guide length for ADAR-based techniques. Our findings indicate that 498/566 (88%) of the SNVs suitable for endogenous-ADAR do not have such off-target similar regions, suggesting that these variants are safer in terms of off-target effects.</p>
<p t="i" title="Paragraph Indented" apt_id="252" id="p_252">Another concern is unintended bystander edits in close proximity to the target nucleotide. Even when the deaminase successfully approaches its target, it may inadvertently edit other nucleotides of the same type in the immediate vicinity. To explore this issue, we focused on the 20 bases surrounding the variant and quantified the number of adenosines in this region. Utilizing the recent prediction model of AlphaMissense [<bibcit rid="1032" title="bibcit" href="#" contenteditable="false" id="bibcit_253" sno="32" apt_id="253">32</bibcit>], we further evaluated how many of them were predicted to cause a deleterious effect if editing occurs. We observed an average of 5.6 nearby A nucleotides available for potential editing. Out of these, an average of 0.7 was predicted to result in a likely-pathogenic effect when edited. In 347 SNVs (61%) no likely-pathogenic changes were predicted. These calculations may be used as a guideline for considering the adjacent nucleotides surrounding the target SNV while designing the guide. However, in practice, it is unlikely that all will be altered simultaneously. Also, A-to-I(G) editing does not have the potential to unintentionally introduce new stop codons (UAA, UAG, or UGA), making it a safer option in terms of bystander edits, compared to other base-editing methods. Encouragingly, a recent study demonstrated that the inclusion of an extra chemical compound alongside the gRNA significantly diminishes the occurrence of bystander edits [<bibcit rid="736" title="bibcit" href="#" contenteditable="false" id="bibcit_254" sno="13" apt_id="254">13</bibcit>]. Finally, it is worth mentioning again that even if a clinically deleterious mistake occurs, errors at the RNA level have only a transient effect.</p>
</sect2><sect2 id="sect2_255" apt_id="255"><ti title="Heading 2" apt_id="256" id="ti_256">Frequency evaluation of variants amenable to endogenous-ADAR</ti>
<p t="fl" title="Paragraph No Indent" apt_id="257" id="p_257">When designing a therapy, considering its applicability to a larger patient population often favors common variants over rare ones. However, determining the frequency of a specific germline mutation in the general population is challenging due to genetic diversity and the rarity of most SNVs. The gnomAD database [<bibcit rid="1087" title="bibcit" href="#" contenteditable="false" id="bibcit_258" sno="35" apt_id="258">35</bibcit>] compiles data from over 195 000 individuals worldwide, enabling approximate estimates of mutation frequency in the general population. gnomAD is exclusively based on adults, and individuals with known Mendelian diseases have been excluded. Consequently, the deleterious mutations documented are mostly heterozygous and found in genes associated with recessive diseases or dominant diseases with incomplete penetrance. Furthermore, gnomAD’s representation varies across populations, with an over-representation of European participants, leading to imprecise estimations of genetic variants and an underrepresentation of many communities, including those of African, Middle Eastern, and Oceanian descent [<bibcit rid="1105" title="bibcit" href="#" contenteditable="false" id="bibcit_259" sno="36" apt_id="259">36</bibcit>]. Out of the 566 putative cancer-risk SNVs suitable for endogenous-ADAR editing, 102 were detected as present at least once in gnomAD (with an average frequency of 1.82*10<sup apt_id="260" id="sup_260">−5</sup>). Variants that are present in gnomAD may be interesting candidates for future treatment consideration, but caution is warranted as discussed above. The two most frequent G &gt; A SNVs in the dataset were <i apt_id="261" id="i_261">RET</i> c.1438G &gt; A (p.Glu480Lys) and <i apt_id="262" id="i_262">TP53</i> c.91G &gt; A (p.Val31Ile), with frequencies of 2.7*10<sup apt_id="263" id="sup_263">−4</sup> and 2.5*10<sup apt_id="264" id="sup_264">−4,</sup> respectively. <i apt_id="265" id="i_265">ATM</i> (mutated in ataxia telangectasia) and <i apt_id="266" id="i_266">TP53</i> (mutated in Li-Fraumeni syndrome) stood out with the highest variant count in gnomAD, aligning with their well-established significance across a spectrum of cancers, along with the considerable length of <i apt_id="267" id="i_267">ATM</i>.</p>
<p t="i" title="Paragraph Indented" apt_id="268" id="p_268"><url title="URL" type="uri" href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcaf016#supplementary-data" apt_id="269" id="url_269">Supplementary Table S2</url> summarizes the pathogenic SNVs that are suitable for endogenous-ADAR, including added data we provided regarding the number of bystander edits and off-target hits. Note that in 313 out of the 567 variants, no off-target and no pathogenic bystander edit was observed, rendering them ideal targets in terms of safety.</p>
<p t="i" title="Paragraph Indented" apt_id="270" id="p_270">Pediatric cancer predisposition syndromes present a potential use case for endogenous-ADAR. However, application in adult cancer risk populations may also be possible, albeit more challenging given the potential gene/environment mediators. Yet, delayed onset could present an advantage, providing a greater window of opportunity for intervention. We thus repeated the analysis using the high-penetrance gene list compiled by Memorial Sloan Kettering [<bibcit rid="1004" title="bibcit" href="#" contenteditable="false" id="bibcit_271" sno="30" apt_id="271">30</bibcit>], comprised of 239 high-penetrance pathogenic germline SNVs associated with different cancer types in adults (Methods). We found that 48/239 (20%) are suitable for endogenous-ADAR. The distribution of these SNVs across different cancer subtypes is illustrated in Fig. <figcit rid="238" title="figcit" href="#" contenteditable="false" id="figcit_272" sno="1" apt_id="272">1</figcit>b. A noteworthy finding is that endogenous-ADAR can address all SNVs within the <i apt_id="273" id="i_273">RET</i> gene associated with thyroid cancer.</p>
<p t="i" title="Paragraph Indented" apt_id="274" id="p_274">For 47 out of the 48 (98%) endogenous-ADAR targetable SNVs, no off-target sites were detected. Regarding potential bystander edits, we found an average of 5.2 A nucleotides per variant, of which 0.9 were predicted to be pathogenic. For 23 (48%) SNVs, no deleterious change is predicted. GnomAD reports frequency for 7 endogenous-ADAR targetable SNVs (with an average frequency of 1.02*10<sup apt_id="275" id="sup_275">−5</sup>), of which 4 were identified in the <i apt_id="276" id="i_276">TP53</i> gene and 2 in the <i apt_id="277" id="i_277">MLH1</i> gene.</p>
</sect2><sect2 id="sect2_278" apt_id="278"><ti title="Heading 2" apt_id="279" id="ti_279">Targeting cancer driver mutations as potential cancer treatments</ti>
<p t="fl" title="Paragraph No Indent" apt_id="280" id="p_280">Selecting optimal targets for correction in mature cancer tissue poses challenges due to the presence of numerous mutations, often unique to each individual. Consequently, a personalized approach involving the design of a tailored editor for each patient becomes necessary. Rather than targeting “passenger” mutations, it is reasonable to assume that targeting driver mutations will have more impact on clinically relevant tumor progression. For this analysis, we used the driver mutation list generated by the PCAWG project [<bibcit rid="1123" title="bibcit" href="#" contenteditable="false" id="bibcit_281" sno="37" apt_id="281">37</bibcit>], which ranks variants in a genomic element based on recurrence, functional impact, and expected driver patterns. PCAWG identifies probable driver mutations by comparing the observed mutation burden to the background rate [<bibcit rid="1123" title="bibcit" href="#" contenteditable="false" id="bibcit_282" sno="37" apt_id="282">37</bibcit>]. We analyzed 5 788 driver mutations overall identified in 2 010 patients from 36 different cancer types. The average number of driver mutations per patient was 2.9 (±2.4). Colorectal adenocarcinoma ranked highest on the list with an average of 7.4 (±7.1) driver mutations per patient. We found that 955/5 788 (16%) of the driver mutations were suitable for endogenous-ADAR (Fig. <figcit rid="284" title="figcit" href="#" contenteditable="false" id="figcit_283" sno="2" apt_id="283">2</figcit>). Of these variants, 857/955 (90%) had no detected off-target events, and on average, bystander edits extended over 4.7 nucleotides, with 1.9 predicted to be likely pathogenic. In 281 of the variants (29%) no likely-pathogenic changes were predicted. The comparison to the genome was performed utilizing a normal reference genome. Consequently, our calculations may not be entirely accurate when applied to a cancerous tissue, given the abnormal nature of the tumor genome that contains variations such as duplication events.</p>
<fig id="fig_284" prefix="Figure" suffix="." sno="2" type="arabic" sub-type="" apt_id="284"><ti title="Figure Caption" prefix="Figure" suffix="." sno="2" type="arabic" sub-type="" apt_id="285" id="ti_285">The potential of endogenous-ADAR in reverting cancer driver mutations. a – Basic data information: Representation of the 2 010 patients examined in our analysis, sourced from the pan-cancer analysis of whole genomes (PCAWG) project, categorized by their tumor subtypes, total count of identified driver mutations, and the number of driver mutations found per individual. b – Driver mutations that are suitable for endogenous-ADAR: For each cancer type the absolute number and the percentage of variants per patient that can be reverted by endogenous-ADAR is shown.</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_f2.jpg" title="Figure" apt_id="286" id="img_286" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="287" id="button_287"><i class="fa-solid fa-pen-to-square" apt_id="288" id="i_288"></i></button></fig></sect2><sect2 id="sect2_289" apt_id="289"><ti title="Heading 2" apt_id="290" id="ti_290">Endogenous-ADAR correction is applicable to at least one-third of cancer cases</ti>
<p t="fl" title="Paragraph No Indent" apt_id="291" id="p_291">Given these results, we turned to calculate for each individual patient the percentage of driver mutations in her/his tumor that could be corrected. Notably, these percentages were conservatively determined by considering in the denominator all the driver mutations expressed by each patient, including the non-SNVs ones such as insertion/deletion mutations. We find that 729/2 010 (36%) patients had at least one endogenous-ADAR targetable driver mutation; in 505/2 010 (25%) patients at least 30% of the driver mutations were amenable to endogenous-ADAR; and in 310/2 010 (15%) patients at least 50% of their mutations were treatable by endogenous-ADAR. Remarkably, in 91 (5%) patients, all driver mutations were suitable for endogenous-ADAR (81 patients had one driver mutation and 10 patients had two driver mutations). If reverting just one driver mutation per tumor has a clinical impact, our results suggest that more than a third of cancer patients may be suitable candidates for endogenous-ADAR therapy. This proportion exceeds the estimated number of patients with actionable mutations targeted by currently available cancer therapies [<bibcit rid="1140" title="bibcit" href="#" contenteditable="false" id="bibcit_292" sno="38" apt_id="292">38</bibcit>].</p>
</sect2><sect2 id="sect2_293" apt_id="293"><ti title="Heading 2" apt_id="294" id="ti_294">Different cancer types showed varied correction capacity</ti>
<p t="fl" title="Paragraph No Indent" apt_id="295" id="p_295">Different cancer types exhibit diverse distributions of mutation types, suggesting that the number of mutations correctable by endogenous-ADAR may vary among them. To rank cancer types based on their editability, we calculated the ratio of editable variants to the total number of mutations in each cancer type and evaluated the statistical significance of these editable proportions in comparison to other cancer types. Ten cancer types exhibited significantly higher editing potential by endogenous-ADAR, with the highest being pancreatic and liver (Table <tbcit rid="298" title="tbcit" href="#" contenteditable="false" id="tbcit_296" sno="1" apt_id="296">1</tbcit>). Of interest, liver cancers are especially relevant, as current research in endogenous-ADAR focuses on the liver given the feasibility of delivering the therapy through direct intravenous injections [<bibcit rid="1158" title="bibcit" href="#" contenteditable="false" id="bibcit_297" sno="39" apt_id="297">39</bibcit>].</p>
<tableg id="tableg_298" sub-type="" prefix="Table" suffix="." sno="1" type="arabic" apt_id="298"><ti title="Table Caption" prefix="Table" suffix="." sno="1" type="arabic" sub-type="" apt_id="299" id="ti_299">Cancer types that demonstrate significantly higher editing potential relative to others, when comparing cancer types in pairs. Ten such cancer types were detected for endogenous-ADAR.</ti>
<table frame="topbot" width="auto" apt_id="300" id="table_300"><colgroup apt_id="301" id="colgroup_301"><col align="left" apt_id="302" id="col_302" /><col align="left" apt_id="303" id="col_303" /><col align="left" apt_id="304" id="col_304" /><col align="left" apt_id="305" id="col_305" /><col align="left" apt_id="306" id="col_306" /></colgroup>
<thead apt_id="307" id="thead_307">
<tr apt_id="308" id="tr_308">
<th title="Table Column Head" apt_id="309" id="th_309">
<p apt_id="310" id="p_310">Cancer Types</p>
</th>
<th title="Table Column Head" apt_id="311" id="th_311">
<p apt_id="312" id="p_312">No. of patients Involved</p>
</th>
<th title="Table Column Head" apt_id="313" id="th_313">
<p apt_id="314" id="p_314">No. of patients against</p>
</th>
<th title="Table Column Head" apt_id="315" id="th_315">
<p apt_id="316" id="p_316">p-value</p>
</th>
<th title="Table Column Head" apt_id="317" id="th_317">
<p apt_id="318" id="p_318">FDR</p>
</th>
</tr>
</thead>
<tbody apt_id="319" id="tbody_319">
<tr apt_id="320" id="tr_320">
<td title="Table Column Body" apt_id="321" id="td_321">
<p apt_id="322" id="p_322">Panc-AdenoCA</p>
</td>
<td title="Table Column Body" apt_id="323" id="td_323">
<p apt_id="324" id="p_324">229</p>
</td>
<td title="Table Column Body" apt_id="325" id="td_325">
<p apt_id="326" id="p_326">1781</p>
</td>
<td title="Table Column Body" apt_id="327" id="td_327">
<p apt_id="328" id="p_328">5.07E-10</p>
</td>
<td title="Table Column Body" apt_id="329" id="td_329">
<p apt_id="330" id="p_330">1.83E-08</p>
</td>
</tr>
<tr apt_id="331" id="tr_331">
<td title="Table Column Body" apt_id="332" id="td_332">
<p apt_id="333" id="p_333">Liver-HCC</p>
</td>
<td title="Table Column Body" apt_id="334" id="td_334">
<p apt_id="335" id="p_335">271</p>
</td>
<td title="Table Column Body" apt_id="336" id="td_336">
<p apt_id="337" id="p_337">1739</p>
</td>
<td title="Table Column Body" apt_id="338" id="td_338">
<p apt_id="339" id="p_339">1.30E-09</p>
</td>
<td title="Table Column Body" apt_id="340" id="td_340">
<p apt_id="341" id="p_341">2.34E-08</p>
</td>
</tr>
<tr apt_id="342" id="tr_342">
<td title="Table Column Body" apt_id="343" id="td_343">
<p apt_id="344" id="p_344">Prost-AdenoCA</p>
</td>
<td title="Table Column Body" apt_id="345" id="td_345">
<p apt_id="346" id="p_346">105</p>
</td>
<td title="Table Column Body" apt_id="347" id="td_347">
<p apt_id="348" id="p_348">1905</p>
</td>
<td title="Table Column Body" apt_id="349" id="td_349">
<p apt_id="350" id="p_350">4.60E-06</p>
</td>
<td title="Table Column Body" apt_id="351" id="td_351">
<p apt_id="352" id="p_352">4.14E-05</p>
</td>
</tr>
<tr apt_id="353" id="tr_353">
<td title="Table Column Body" apt_id="354" id="td_354">
<p apt_id="355" id="p_355">CNS-Oligo</p>
</td>
<td title="Table Column Body" apt_id="356" id="td_356">
<p apt_id="357" id="p_357">18</p>
</td>
<td title="Table Column Body" apt_id="358" id="td_358">
<p apt_id="359" id="p_359">1992</p>
</td>
<td title="Table Column Body" apt_id="360" id="td_360">
<p apt_id="361" id="p_361">4.35E-06</p>
</td>
<td title="Table Column Body" apt_id="362" id="td_362">
<p apt_id="363" id="p_363">4.14E-05</p>
</td>
</tr>
<tr apt_id="364" id="tr_364">
<td title="Table Column Body" apt_id="365" id="td_365">
<p apt_id="366" id="p_366">ColoRect-AdenoCA</p>
</td>
<td title="Table Column Body" apt_id="367" id="td_367">
<p apt_id="368" id="p_368">52</p>
</td>
<td title="Table Column Body" apt_id="369" id="td_369">
<p apt_id="370" id="p_370">1958</p>
</td>
<td title="Table Column Body" apt_id="371" id="td_371">
<p apt_id="372" id="p_372">6.15E-04</p>
</td>
<td title="Table Column Body" apt_id="373" id="td_373">
<p apt_id="374" id="p_374">4.43E-03</p>
</td>
</tr>
<tr apt_id="375" id="tr_375">
<td title="Table Column Body" apt_id="376" id="td_376">
<p apt_id="377" id="p_377">Eso-AdenoCa</p>
</td>
<td title="Table Column Body" apt_id="378" id="td_378">
<p apt_id="379" id="p_379">91</p>
</td>
<td title="Table Column Body" apt_id="380" id="td_380">
<p apt_id="381" id="p_381">1919</p>
</td>
<td title="Table Column Body" apt_id="382" id="td_382">
<p apt_id="383" id="p_383">9.08E-04</p>
</td>
<td title="Table Column Body" apt_id="384" id="td_384">
<p apt_id="385" id="p_385">5.45E-03</p>
</td>
</tr>
<tr apt_id="386" id="tr_386">
<td title="Table Column Body" apt_id="387" id="td_387">
<p apt_id="388" id="p_388">Kidney-RCC</p>
</td>
<td title="Table Column Body" apt_id="389" id="td_389">
<p apt_id="390" id="p_390">119</p>
</td>
<td title="Table Column Body" apt_id="391" id="td_391">
<p apt_id="392" id="p_392">1891</p>
</td>
<td title="Table Column Body" apt_id="393" id="td_393">
<p apt_id="394" id="p_394">1.48E-03</p>
</td>
<td title="Table Column Body" apt_id="395" id="td_395">
<p apt_id="396" id="p_396">7.60E-03</p>
</td>
</tr>
<tr apt_id="397" id="tr_397">
<td title="Table Column Body" apt_id="398" id="td_398">
<p apt_id="399" id="p_399">Stomach-AdenoCA</p>
</td>
<td title="Table Column Body" apt_id="400" id="td_400">
<p apt_id="401" id="p_401">52</p>
</td>
<td title="Table Column Body" apt_id="402" id="td_402">
<p apt_id="403" id="p_403">1958</p>
</td>
<td title="Table Column Body" apt_id="404" id="td_404">
<p apt_id="405" id="p_405">4.92E-03</p>
</td>
<td title="Table Column Body" apt_id="406" id="td_406">
<p apt_id="407" id="p_407">2.21E-02</p>
</td>
</tr>
<tr apt_id="408" id="tr_408">
<td title="Table Column Body" apt_id="409" id="td_409">
<p apt_id="410" id="p_410">CNS-Medullo</p>
</td>
<td title="Table Column Body" apt_id="411" id="td_411">
<p apt_id="412" id="p_412">75</p>
</td>
<td title="Table Column Body" apt_id="413" id="td_413">
<p apt_id="414" id="p_414">1935</p>
</td>
<td title="Table Column Body" apt_id="415" id="td_415">
<p apt_id="416" id="p_416">5.69E-03</p>
</td>
<td title="Table Column Body" apt_id="417" id="td_417">
<p apt_id="418" id="p_418">2.28E-02</p>
</td>
</tr>
<tr apt_id="419" id="tr_419">
<td title="Table Column Body" apt_id="420" id="td_420">
<p apt_id="421" id="p_421">Panc-Endocrine</p>
</td>
<td title="Table Column Body" apt_id="422" id="td_422">
<p apt_id="423" id="p_423">52</p>
</td>
<td title="Table Column Body" apt_id="424" id="td_424">
<p apt_id="425" id="p_425">1958</p>
</td>
<td title="Table Column Body" apt_id="426" id="td_426">
<p apt_id="427" id="p_427">6.46E-03</p>
</td>
<td title="Table Column Body" apt_id="428" id="td_428">
<p apt_id="429" id="p_429">2.32E-02</p>
</td>
</tr>
</tbody>
</table>
</tableg></sect2><sect2 id="sect2_430" apt_id="430"><ti title="Heading 2" apt_id="431" id="ti_431">Even low editing efficacy might be beneficial</ti>
<p t="fl" title="Paragraph No Indent" apt_id="432" id="p_432">Another aspect that necessitates further analysis pertains to the proportion of cells modified through therapeutic endogenous-ADAR. Based on current replicated studies, the efficacy of editing targeted cells is reported to range from 60% to 80% [<bibcit rid="1069" title="bibcit" href="#" contenteditable="false" id="bibcit_433" sno="34" apt_id="433">34</bibcit>] when carefully engineering the optimal guides and incorporating precise chemical modifications. This gives rise to concerns in the context of cancer treatment, as tumor cells that evade editing may continue to progress. To quantify the potential impact of endogenous-ADAR therapy, we applied probabilistic arguments. For simplicity, we assume that all cancer cells exhibit the correctable driver mutations in that cancer type, and first calculated the aggregate proportion of cells that would be affected when targeting one, two, or three driver mutations simultaneously. We assume here a scenario in which (for multiple mutations), it is only the combination of all of these driver mutations that makes the cell malignant, and therefore successful editing of one driver mutation per cell suffices [<bibcit rid="1176" title="bibcit" href="#" contenteditable="false" id="bibcit_434" sno="40" apt_id="434">40</bibcit>] (Fig. <figcit rid="436" title="figcit" href="#" contenteditable="false" id="figcit_435" sno="3" apt_id="435">3</figcit>a). For instance, considering a lower bound of successful editing of just 60% and tumor cells presenting 1,2, or 3 driver mutations, the fraction of treatable cells would be 60%, 84%, and 94%, respectively (Methods).</p>
<fig id="fig_436" prefix="Figure" suffix="." sno="3" type="arabic" sub-type="" apt_id="436"><ti title="Figure Caption" prefix="Figure" suffix="." sno="3" type="arabic" sub-type="" apt_id="437" id="ti_437">Calculation of the editing impact. The cumulative percentage of cells to undergo editing, presented by the therapeutic editing capability and the quantity of targeted variants. a – when editing one driver mutation per cell is adequate. b – when editing two driver mutations per cell is required.</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_f3.jpg" title="Figure" apt_id="438" id="img_438" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="439" id="button_439"><i class="fa-solid fa-pen-to-square" apt_id="440" id="i_440"></i></button></fig>
<p t="i" title="Paragraph Indented" apt_id="441" id="p_441">While these calculations are based on theoretical assumptions that are likely to be more complicated in the real cancer environment, it is inferred that a substantial number of patients stand to gain from endogenous-ADAR treatment, even when a low editing threshold is employed. As technological advancements continue, the editing efficacy is likely to be high.</p>
</sect2><sect2 id="sect2_442" apt_id="442"><ti title="Heading 2" apt_id="443" id="ti_443">Endogenous-ADAR correction of key cancer drivers: a few cases of considerable translational interest</ti>
<p t="fl" title="Paragraph No Indent" apt_id="444" id="p_444">To demonstrate its clinical relevance in the context of cancer, we highlight here three major well known cancer drivers that are suitable for endogenous-ADAR out of many such examples that are provided in the various Tables in Results. One obvious candidate is the tumor protein p53, encoded by the gene <i apt_id="445" id="i_445">TP53,</i> one of the most frequently mutated genes in cancer, acting as both tumor suppressor and oncogene and playing a crucial role in regulating cell cycle arrest and apoptosis [<bibcit rid="1190" title="bibcit" href="#" contenteditable="false" id="bibcit_446" sno="41" apt_id="446">41</bibcit>]. <i apt_id="447" id="i_447">TP53</i> germline mutations are found in Li-Fraumeni syndrome [<bibcit rid="1204" title="bibcit" href="#" contenteditable="false" id="bibcit_448" sno="42" apt_id="448">42</bibcit>], while somatic mutations are common in almost all cancer types. The most prevalent <i apt_id="449" id="i_449">TP53</i> variant, according to Cancer Genome Data (CGD) [<bibcit rid="1219" title="bibcit" href="#" contenteditable="false" id="bibcit_450" sno="43" apt_id="450">43</bibcit>], is the R175H variant. This is a G &gt; A missense variant that may serve as a good target for endogenous-ADAR in a variety of cancer types. Another frequently observed hotspot mutation in <i apt_id="451" id="i_451">TP53</i> is R273H, which is also a G &gt; A missense variant. Both variants occur within the DNA binding domain of the TP53 protein and are known to disrupt normal gene function [<bibcit rid="1237" title="bibcit" href="#" contenteditable="false" id="bibcit_452" sno="44" apt_id="452">44</bibcit>, <bibcit rid="1255" title="bibcit" href="#" contenteditable="false" id="bibcit_453" sno="45" apt_id="453">45</bibcit>]. In the case of the first variant, there are two possible pathogenic bystander edits, whereas for the second variant, only one is observed (Fig. <figcit rid="455" title="figcit" href="#" contenteditable="false" id="figcit_454" sno="4" apt_id="454">4</figcit>). No distant off-target hits were detected for either variant.</p>
<fig id="fig_455" prefix="Figure" suffix="." sno="4" type="arabic" sub-type="" apt_id="455"><ti title="Figure Caption" prefix="Figure" suffix="." sno="4" type="arabic" sub-type="" apt_id="456" id="ti_456">Targatable key cancer driver mutations. Illustration of six common cancer driver mutations in the <i apt_id="457" id="i_457">TP53</i>, <i apt_id="458" id="i_458">KRAS</i>, <i apt_id="459" id="i_459">IDH1</i>, and <i apt_id="460" id="i_460">IDH2</i> genes, amenable to endogenous-ADAR.</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARCAN/zcaf016//images/zcaf016_f4.jpg" title="Figure" apt_id="461" id="img_461" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="462" id="button_462"><i class="fa-solid fa-pen-to-square" apt_id="463" id="i_463"></i></button></fig>
<p t="i" title="Paragraph Indented" apt_id="464" id="p_464">A second interesting example is Isocitrate dehydrogenases (<i apt_id="465" id="i_465">IDH1</i> and <i apt_id="466" id="i_466">IDH2</i>), enzyme-encoding genes that are frequently mutated in gliomas, acute myeloid leukemia, cholangiocarcinoma, chondrosarcoma, and thyroid carcinoma [<bibcit rid="1269" title="bibcit" href="#" contenteditable="false" id="bibcit_467" sno="46" apt_id="467">46</bibcit>]. Pathogenic mutations in IDH genes often occur at specific arginine residues (R132 for <i apt_id="468" id="i_468">IDH1</i>, R140 or R172 for <i apt_id="469" id="i_469">IDH2</i>), which are vital for isocitrate recognition. Consequently, these IDH variants have been extensively investigated as potential therapeutic targets for cancer treatment [<bibcit rid="1287" title="bibcit" href="#" contenteditable="false" id="bibcit_470" sno="47" apt_id="470">47</bibcit>]. Interestingly, all three variants are G &gt; A missense SNVs, rendering them suitable for endogenous ADAR. Predictions suggest that 2–3 bystander edits could be pathogenic upon editing (Fig. <figcit rid="455" title="figcit" href="#" contenteditable="false" id="figcit_471" sno="4" apt_id="471">4</figcit>), with no detected off-target hits.</p>
<p t="i" title="Paragraph Indented" apt_id="472" id="p_472">Finally, the <i apt_id="473" id="i_473">KRAS</i> proto-oncogene is a key player in cell signaling pathways governing cell growth and division. Its high occurrence of mutations across various cancers renders it a central subject in cancer research and therapy [<bibcit rid="1305" title="bibcit" href="#" contenteditable="false" id="bibcit_474" sno="48" apt_id="474">48</bibcit>]. Among somatic mutations in KRAS, the most common one is G12D, which is also the most common KRAS mutation in carcinomas [<bibcit rid="1323" title="bibcit" href="#" contenteditable="false" id="bibcit_475" sno="49" apt_id="475">49</bibcit>]. This is a G &gt; A SNV, and our investigation reveals that no pathogenic bystander edits or distant off-targets are detected for this variant, making it a safe therapeutic target for endogenous-ADAR.</p>
<p t="i" title="Paragraph Indented" apt_id="476" id="p_476">Several strategies have been purposed to treat patients whose tumors have this somatic variant. Though no clinical trial results are available to date, promising results were seen in pre-clinical models [<bibcit rid="1340" title="bibcit" href="#" contenteditable="false" id="bibcit_477" sno="50" apt_id="477">50</bibcit>]. Thus, to date, no studies have assessed resistance mechanisms to G12D inhibitors, but resistance to treatment has been observed for KRAS-G12C inhibitors and may inform potential resistance mechanisms for G12D inhibitors. The approach we suggest here to edit the mutation might also lead to such resistance, evading the therapy. Yet, in the case of base editing, it is easier to re-tailor the guide to the patient once new mutations arise. This approach thus warrants further investigation.</p>
</sect2></sect1><sect1 id="sect1_478" sec-type="discussion" apt_id="478"><ti title="Heading 1" apt_id="479" id="ti_479">Discussion</ti>
<p t="fl" title="Paragraph No Indent" apt_id="480" id="p_480">This study presents a computational framework for exploring the capabilities of endogenous-ADAR editors in cancer risk reduction/prevention and cancer treatment. We first systematically studied the potential application scope of endogenous-ADAR editing to correct key mutations in childhood cancer predisposition syndromes, as well as high-penetrance germline mutations associated with cancer in adults. This approach could diminish the severity or impact of inherited cancer syndromes, changing the field of cancer risk. Complete resolution of germline mutations using endogenous-ADAR is still a distant goal, due to limited efficiency, but even partial correction might be beneficial in postponing the onset of cancer to a later age. Additionally, while RNA editing is transient, which can serve as an advantage when monitoring errors and unintended edits, it presents challenges in terms of patient compliance and burden. This is particularly true for cancer prevention which requires long-term therapy administration. Clearly, the benefits and drawbacks should be carefully weighed for each case. An inspiring example is of women carrying the mutated <i apt_id="481" id="i_481">BRCA1</i> or <i apt_id="482" id="i_482">BRCA2</i> genes, who are advised to undergo prophylactic removal of the uterus and ovaries. For these individuals, employing such a therapy to delay cancer development becomes crucial as it permits them to defer the surgery until after their fertile years.</p>
<p t="i" title="Paragraph Indented" apt_id="483" id="p_483">Second, we have turned to study the extent by which endogenous-ADAR may potentially be harnessed for cancer treatment. For many of the patients studied in PCAWG, covering multiple cancer types, endogenous-ADAR can potentially target at least one identified driver mutation. Considering the successful application of lipid-nanoparticles (LNPs) as therapeutic agents in different cancer types [<bibcit rid="1358" title="bibcit" href="#" contenteditable="false" id="bibcit_484" sno="51" apt_id="484">51</bibcit>], the prospects of delivering endogenous-ADAR to various cancers seem promising, as it requires the insertion of only a small payload containing a gRNA into the cell. While small-molecule targeted therapies may be preferable when available, we highlight the potential of Endogenous-ADAR as a valuable treatment option in cases where other therapies are lacking or as an adjunct to existing treatments.</p>
<p t="i" title="Paragraph Indented" apt_id="485" id="p_485">Off-target edits pose a serious safety concern. This is particularly true in the context of cancer prevention, where patients do not exhibit a phenotypic condition at the time of treatment, and any adverse outcomes resulting from off-target effects can undermine the potential benefits of the therapy. In contrast, when targeting somatic mutations within a developed tumor, the “price” for treating the disease may be more acceptable. Yet, since driver mutation may be present within non-cancerous cells [<bibcit rid="1375" title="bibcit" href="#" contenteditable="false" id="bibcit_486" sno="52" apt_id="486">52</bibcit>], the safety profile of the editor should be considered. A thorough investigation of potential off-target effects associated with the variants mentioned in the paper revealed a low probability of off-target occurrences. Variants with a sparse number of detected off-target sites may still serve as viable therapeutic targets, since the majority of genomic sites are non-coding, making unintended edits not clinically meaningful. Secondly, even if these off-target sites fall within coding regions, they are not necessarily expressed in the targeted tissue, underscoring another advantage of RNA editing over DNA editing. We also computed the potential bystander edits that may arise when the deaminase edits nucleotides in close proximity to the target site, and the number of those which are predicted to have a deleterious effect based on current available models.</p>
<p t="i" title="Paragraph Indented" apt_id="487" id="p_487">An additional factor to consider is the degree of editing achieved per target. Reasonably, if the appropriate target is chosen, the mere editing of a subset of cells or RNA copies could still yield an effect in suppressing tumor growth. Moreover, combining multiple driver mutation targets could lead to improved results. A possible drawback might be that the treatment could lead to the clonal selection of cells not covered by the therapy. However, if new mutations arise, adjustments can be made to tailor the therapy accordingly. It is likely that the strength of the presented technique lies in slowing down disease progression rather than providing a complete cure for cancer. To delve deeper into these aspects and better grasp the potential of endogenous-ADAR in cancer-related applications, further <i apt_id="488" id="i_488">in vivo</i> research is necessary to confirm targeting specificity to specific cancer types and to minimize potential risk of off-target effects. Lastly, the native ADAR enzyme requires a specific motif, particularly necessitating the absence of a G nucleotide 5′ to the edited A. However, recent studies have identified strategies to overcome this constraint [<bibcit rid="1392" title="bibcit" href="#" contenteditable="false" id="bibcit_489" sno="53" apt_id="489">53</bibcit>], hence it was not considered in our analysis. In the same manner, 5′-CAN-3′ sequences are generally disfavored and correction at these sites is challenging, but recent advancements propose methods to address this issue [<bibcit rid="1410" title="bibcit" href="#" contenteditable="false" id="bibcit_490" sno="54" apt_id="490">54</bibcit>]. Secondary structures of the target transcript region can also impact proper binding of the gRNA to the desired region. All of these factors should be taken into account when carefully planning a guide for Endogenous-ADAR therapy.</p>
<p t="i" title="Paragraph Indented" apt_id="491" id="p_491">In this study, we investigated the prospects of endogenous-ADAR to target inherited variants associated with cancer risk in pediatric syndromes and adults with high-penetrance disease, as well as treating cancer by correcting driver mutations in tumors. Our analysis was conducted on external databases that might disproportionately represent specific populations in comparison to others. Yet, our findings portray a favorable and encouraging landscape of correctable mutations in cancer, pointing to the possibility of future leveraging the unique capabilities of endogenous-ADAR therapy towards clinical cancer risk/prevention and treatment outcomes.</p>
</sect1><sect1 sec-type="ack" apt_id="492" id="sect1_492"><ti title="Acknowledgement Heading" apt_id="493" id="ti_493">Acknowledgements</ti>
<p t="fl" title="Paragraph No Indent" apt_id="494" id="p_494">This work was supported by the Israel Science Foundation grants 231/21 and grant #0002315 from MOS to E.Y.L and in part by the Intramural Research Program of the NIH, NCI. E.Y.L is a fellow at the Israel Institute for Advanced Studies, Jerusalem. The graphical abstract was created in BioRender. zilbert, o. (2025) <url title="URL" type="uri" href="https://BioRender.com/y162n8v" apt_id="495" id="url_495">https://BioRender.com/y162n8v</url><query><button type="button" title="Copy Editor to Author-AU: Please ensure all 'conflicts of interest' (or 'disclosures') have been included for you and your co-authors, and that this section is correct. Edit the text directly if changes are required." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="19" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">19</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please check that funding is recorded in a separate funding section, if applicable. Use the full official names of any funding bodies and include any grant numbers. Insert any changes to the funding section directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="20" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">20</span></button></query>.</p>
<p t="i" title="Paragraph Indented" apt_id="500" id="p_500"><i apt_id="501" id="i_501">Author contributions</i>: RM-R was responsible for desiging the research, collecting databases, generating the graphs, writing the manuscript. AD was responsible for desiging the research, writing the code. SP was responsible for anaylsing data. PSR was responsible for desiging the research. GND was aiding in collecting and analysing data. SBA contributed to conceptualization. AAS and EE provided feedback on the results and helped editing the manuscript. ER and EYL were responsible for conceptualization, supervision and editing the manuscript.</p>
<p t="i" title="Paragraph Indented" apt_id="502" id="p_502">The work is submitted in partial fulfillment of the requirements for the PhD of RM-R.</p>
</sect1><sect1 id="sect1_503" sec-type="supplementary-data" apt_id="503"><ti title="Heading 1" apt_id="504" id="ti_504">Supplementary data</ti>
<p t="fl" title="Paragraph No Indent" apt_id="505" id="p_505">Supplementary data is available at NAR Cancer online.</p>
</sect1><sect1 id="sect1_506" sec-type="ConflictofInterest" apt_id="506"><ti title="Heading 1" apt_id="507" id="ti_507">Conflict of interest</ti>
<p t="fl" title="Paragraph No Indent" apt_id="508" id="p_508">None declared.</p>
</sect1><sect1 id="sect1_509" sec-type="data-availability" apt_id="509"><ti title="Heading 1" apt_id="510" id="ti_510">Data availability statement</ti>
<p t="fl" title="Paragraph No Indent" apt_id="511" id="p_511">There are no primary data in the paper. The source code used to produce the results and analyses presented in this manuscript are available on a Zenodo at: 10.5281/zenodo.14787914 <url title="URL" type="uri" href="https://doi.org/10.5281/zenodo.14778569" apt_id="512" id="url_512">https://doi.org/10.5281/zenodo.14778569</url>.</p>
</sect1><sect1 id="sect1_513" sec-type="clinvar-dataset" apt_id="513"><ti title="Heading 1" apt_id="514" id="ti_514"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="515" id="p_515">The ClinVar dataset, a publicly accessible repository of clinically relevant genomic variations managed by the National Center for Biotechnology Information (NCBI), was retrieved from UCSC, version November 2021, and can be accessed at <url title="URL" type="uri" href="https://hgdownload.soe.ucsc.edu/goldenpath/archive/hg38/clinvar/2021-11/" apt_id="516" id="url_516">https://hgdownload.soe.ucsc.edu/goldenpath/archive/hg38/clinvar/2021-11/</url>. Proteome-wide missense variant effect predictions from the alphaMissense project were obtained from their community resource repository, which can be accessed at <url title="URL" type="uri" href="https://console.cloud.google.com/storage/browser/dm_alphamissense" apt_id="517" id="url_517">https://console.cloud.google.com/storage/browser/dm_alphamissense</url>. The Memorial Sloan Kettering's SIGNAL db is an open-access database available at <url title="URL" type="uri" href="https://www.signaldb.org/" apt_id="518" id="url_518">https://www.signaldb.org/</url>. The PCWAG database was downloaded following an application for access to the ICGC Controlled Data<query><button type="button" title="Copy Editor to Author-AU: Supplementary Data having 'False' value in metadata but supplementary section found in pre-edit file. Please check." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="21" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">21</span></button></query>.</p>
</sect1></bdy><bm apt_id="521" id="bm_521"><ref type="arabic" sno="1" suffix="." id="ref_522" apt_id="522"><ti title="Bibliography Heading" apt_id="523" id="ti_523">References</ti><bib type="arabic" id="bib_524" sno="1" suffix="." apt_id="524"><jcit apt_id="525" id="jcit_525"><au apt_id="526" id="au_526"><s title="Surname" apt_id="527" id="s_527">Landrum</s><f title="First name" apt_id="528" id="f_528">MJ</f></au>, <au apt_id="529" id="au_529"><s title="Surname" apt_id="530" id="s_530">Lee</s><f title="First name" apt_id="531" id="f_531">JM</f></au>, <au apt_id="532" id="au_532"><s title="Surname" apt_id="533" id="s_533">Benson</s><f title="First name" apt_id="534" id="f_534">M</f></au>, <etal title="etal" apt_id="535" id="etal_535">et al.</etal> <at title="Article Title" apt_id="536" id="at_536">ClinVar: public archive of interpretations of clinically relevant variants</at>. <pt title="Periodical Title" apt_id="537" id="pt_537">Nucleic Acids Res</pt> <yr title="Year" apt_id="538" id="yr_538">2016</yr>;<v title="Volume" apt_id="539" id="v_539">44</v>:<pages title="Pages" apt_id="540" id="pages_540">D862–8</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gkv1222" apt_id="541" id="url_541">https://doi.org/10.1093/nar/gkv1222</url> </jcit></bib><bib type="arabic" id="bib_542" sno="2" suffix="." apt_id="542"><jcit apt_id="543" id="jcit_543"><au apt_id="544" id="au_544"><s title="Surname" apt_id="545" id="s_545">Dadush</s><f title="First name" apt_id="546" id="f_546">A</f></au>, <au apt_id="547" id="au_547"><s title="Surname" apt_id="548" id="s_548">Merdler-Rabinowicz</s><f title="First name" apt_id="549" id="f_549">R</f></au>, <au apt_id="550" id="au_550"><s title="Surname" apt_id="551" id="s_551">Gorelik</s><f title="First name" apt_id="552" id="f_552">D</f></au>, <etal title="etal" apt_id="553" id="etal_553">et al.</etal> <at title="Article Title" apt_id="554" id="at_554">DNA and RNA base editors can correct the majority of pathogenic single nucleotide variants</at>. <pt title="Periodical Title" apt_id="555" id="pt_555">npj Genom Med</pt> <yr title="Year" apt_id="556" id="yr_556">2024</yr>;<v title="Volume" apt_id="557" id="v_557">9</v>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41525-024-00397-w" apt_id="558" id="url_558">https://doi.org/10.1038/s41525-024-00397-w</url> <query><button type="button" title="Copy Editor to Author-AU: Pages is missing in this reference [2]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="22" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">22</span></button></query></jcit></bib><bib type="arabic" id="bib_561" sno="3" suffix="." apt_id="561"><jcit apt_id="562" id="jcit_562"><au apt_id="563" id="au_563"><s title="Surname" apt_id="564" id="s_564">Booth</s><f title="First name" apt_id="565" id="f_565">BJ</f></au>, <au apt_id="566" id="au_566"><s title="Surname" apt_id="567" id="s_567">Nourreddine</s><f title="First name" apt_id="568" id="f_568">S</f></au>, <au apt_id="569" id="au_569"><s title="Surname" apt_id="570" id="s_570">Katrekar</s><f title="First name" apt_id="571" id="f_571">D</f></au>, <etal title="etal" apt_id="572" id="etal_572">et al.</etal> <at title="Article Title" apt_id="573" id="at_573">RNA editing: expanding the potential of RNA therapeutics</at>. <pt title="Periodical Title" apt_id="574" id="pt_574">Mol Ther</pt> <yr title="Year" apt_id="575" id="yr_575">2023</yr>;<v title="Volume" apt_id="576" id="v_576">31</v>:<pages title="Pages" apt_id="577" id="pages_577">1533–49</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.ymthe.2023.01.005" apt_id="578" id="url_578">https://doi.org/10.1016/j.ymthe.2023.01.005</url> </jcit></bib><bib type="arabic" id="bib_579" sno="4" suffix="." apt_id="579"><jcit apt_id="580" id="jcit_580"><au apt_id="581" id="au_581"><s title="Surname" apt_id="582" id="s_582">Montiel-Gonzalez</s><f title="First name" apt_id="583" id="f_583">MF</f></au>, <au apt_id="584" id="au_584"><s title="Surname" apt_id="585" id="s_585">Vallecillo-Viejo</s><f title="First name" apt_id="586" id="f_586">I</f></au>, <au apt_id="587" id="au_587"><s title="Surname" apt_id="588" id="s_588">Yudowski</s><f title="First name" apt_id="589" id="f_589">GA</f></au>, <etal title="etal" apt_id="590" id="etal_590">et al.</etal> <at title="Article Title" apt_id="591" id="at_591">Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing</at>. <pt title="Periodical Title" apt_id="592" id="pt_592">Proc Natl Acad Sci USA</pt> <yr title="Year" apt_id="593" id="yr_593">2013</yr>;<v title="Volume" apt_id="594" id="v_594">110</v>:<pages title="Pages" apt_id="595" id="pages_595">18285–90</pages>. <url title="URL" type="uri" href="https://doi.org/10.1073/pnas.1306243110" apt_id="596" id="url_596">https://doi.org/10.1073/pnas.1306243110</url> </jcit></bib><bib type="arabic" id="bib_597" sno="5" suffix="." apt_id="597"><jcit apt_id="598" id="jcit_598"><au apt_id="599" id="au_599"><s title="Surname" apt_id="600" id="s_600">Monian</s><f title="First name" apt_id="601" id="f_601">P</f></au>, <au apt_id="602" id="au_602"><s title="Surname" apt_id="603" id="s_603">Shivalila</s><f title="First name" apt_id="604" id="f_604">C</f></au>, <au apt_id="605" id="au_605"><s title="Surname" apt_id="606" id="s_606">Lu</s><f title="First name" apt_id="607" id="f_607">G</f></au>, <etal title="etal" apt_id="608" id="etal_608">et al.</etal> <at title="Article Title" apt_id="609" id="at_609">Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides</at>. <pt title="Periodical Title" apt_id="610" id="pt_610">Nat Biotechnol</pt> <yr title="Year" apt_id="611" id="yr_611">2022</yr>;<v title="Volume" apt_id="612" id="v_612">40</v>:<pages title="Pages" apt_id="613" id="pages_613">1093–102</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41587-022-01225-1" apt_id="614" id="url_614">https://doi.org/10.1038/s41587-022-01225-1</url> </jcit></bib><bib type="arabic" id="bib_615" sno="6" suffix="." apt_id="615"><jcit apt_id="616" id="jcit_616"><au apt_id="617" id="au_617"><s title="Surname" apt_id="618" id="s_618">Kim</s><f title="First name" apt_id="619" id="f_619">J</f></au>, <au apt_id="620" id="au_620"><s title="Surname" apt_id="621" id="s_621">Hu</s><f title="First name" apt_id="622" id="f_622">C</f></au>, <au apt_id="623" id="au_623"><s title="Surname" apt_id="624" id="s_624">Moufawad El Achkar</s><f title="First name" apt_id="625" id="f_625">C</f></au>, <etal title="etal" apt_id="626" id="etal_626">et al.</etal> <at title="Article Title" apt_id="627" id="at_627">Patient-customized oligonucleotide therapy for a rare genetic disease</at>. <pt title="Periodical Title" apt_id="628" id="pt_628">N Engl J Med</pt> <yr title="Year" apt_id="629" id="yr_629">2019</yr>;<v title="Volume" apt_id="630" id="v_630">381</v>:<pages title="Pages" apt_id="631" id="pages_631">1644–52</pages>. <url title="URL" type="uri" href="https://doi.org/10.1056/NEJMoa1813279" apt_id="632" id="url_632">https://doi.org/10.1056/NEJMoa1813279</url> </jcit></bib><bib type="arabic" id="bib_633" sno="7" suffix="." apt_id="633"><jcit apt_id="634" id="jcit_634"><au apt_id="635" id="au_635"><s title="Surname" apt_id="636" id="s_636">Li</s><f title="First name" apt_id="637" id="f_637">X</f></au>, <au apt_id="638" id="au_638"><s title="Surname" apt_id="639" id="s_639">Qian</s><f title="First name" apt_id="640" id="f_640">X</f></au>, <au apt_id="641" id="au_641"><s title="Surname" apt_id="642" id="s_642">Wang</s><f title="First name" apt_id="643" id="f_643">B</f></au>, <etal title="etal" apt_id="644" id="etal_644">et al.</etal> <at title="Article Title" apt_id="645" id="at_645">Programmable base editing of mutated TERT promoter inhibits brain tumour growth</at>. <pt title="Periodical Title" apt_id="646" id="pt_646">Nat Cell Biol</pt> <yr title="Year" apt_id="647" id="yr_647">2020</yr>;<v title="Volume" apt_id="648" id="v_648">22</v>:<pages title="Pages" apt_id="649" id="pages_649">282–8</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41556-020-0471-6" apt_id="650" id="url_650">https://doi.org/10.1038/s41556-020-0471-6</url> </jcit></bib><bib type="arabic" id="bib_651" sno="8" suffix="." apt_id="651"><jcit apt_id="652" id="jcit_652"><au apt_id="653" id="au_653"><s title="Surname" apt_id="654" id="s_654">Bazak</s><f title="First name" apt_id="655" id="f_655">L</f></au>, <au apt_id="656" id="au_656"><s title="Surname" apt_id="657" id="s_657">Haviv</s><f title="First name" apt_id="658" id="f_658">A</f></au>, <au apt_id="659" id="au_659"><s title="Surname" apt_id="660" id="s_660">Barak</s><f title="First name" apt_id="661" id="f_661">M</f></au>, <etal title="etal" apt_id="662" id="etal_662">et al.</etal> <at title="Article Title" apt_id="663" id="at_663">A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes</at>. <pt title="Periodical Title" apt_id="664" id="pt_664">Genome Res</pt> <yr title="Year" apt_id="665" id="yr_665">2014</yr>;<v title="Volume" apt_id="666" id="v_666">24</v>:<pages title="Pages" apt_id="667" id="pages_667">365–76</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gr.164749.113" apt_id="668" id="url_668">https://doi.org/10.1101/gr.164749.113</url> </jcit></bib><bib type="arabic" id="bib_669" sno="9" suffix="." apt_id="669"><jcit apt_id="670" id="jcit_670"><au apt_id="671" id="au_671"><s title="Surname" apt_id="672" id="s_672">Proc A S</s><f title="First name" apt_id="673" id="f_673">ON</f></au>, <au apt_id="674" id="au_674"><s title="Surname" apt_id="675" id="s_675">Neubert</s><f title="First name" apt_id="676" id="f_676">D</f></au>, <au apt_id="677" id="au_677"><s title="Surname" apt_id="678" id="s_678">Lehninger</s><f title="First name" apt_id="679" id="f_679">AL</f></au>, <etal title="etal" apt_id="680" id="etal_680">et al.</etal> <at title="Article Title" apt_id="681" id="at_681">Synthetic polynucleotides and the amino acid code</at>. <pt title="Periodical Title" apt_id="682" id="pt_682">Abstr 6th Internat Congr Biochem</pt> <yr title="Year" apt_id="683" id="yr_683">1960</yr>;<v title="Volume" apt_id="684" id="v_684">86</v>:<pages title="Pages" apt_id="685" id="pages_685">15</pages>.</jcit></bib><bib type="arabic" id="bib_686" sno="10" suffix="." apt_id="686"><jcit apt_id="687" id="jcit_687"><au apt_id="688" id="au_688"><s title="Surname" apt_id="689" id="s_689">Licht</s><f title="First name" apt_id="690" id="f_690">K</f></au>, <au apt_id="691" id="au_691"><s title="Surname" apt_id="692" id="s_692">Hartl</s><f title="First name" apt_id="693" id="f_693">M</f></au>, <au apt_id="694" id="au_694"><s title="Surname" apt_id="695" id="s_695">Amman</s><f title="First name" apt_id="696" id="f_696">F</f></au>, <etal title="etal" apt_id="697" id="etal_697">et al.</etal> <at title="Article Title" apt_id="698" id="at_698">Inosine induces context-dependent recoding and translational stalling</at>. <pt title="Periodical Title" apt_id="699" id="pt_699">Nucleic Acids Res</pt> <yr title="Year" apt_id="700" id="yr_700">2019</yr>;<v title="Volume" apt_id="701" id="v_701">47</v>:<pages title="Pages" apt_id="702" id="pages_702">3–14</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gky1163" apt_id="703" id="url_703">https://doi.org/10.1093/nar/gky1163</url> </jcit></bib><bib type="arabic" id="bib_704" sno="11" suffix="." apt_id="704"><jcit apt_id="705" id="jcit_705"><au apt_id="706" id="au_706"><s title="Surname" apt_id="707" id="s_707">Patterson</s><f title="First name" apt_id="708" id="f_708">JB</f></au>, <au apt_id="709" id="au_709"><s title="Surname" apt_id="710" id="s_710">Samuel</s><f title="First name" apt_id="711" id="f_711">CE</f></au>, . <at title="Article Title" apt_id="712" id="at_712">Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from Human cells: evidence for two forms of the deaminase</at>. <pt title="Periodical Title" apt_id="713" id="pt_713">Mol Cell Biol</pt> <yr title="Year" apt_id="714" id="yr_714">1995</yr>;<v title="Volume" apt_id="715" id="v_715">15</v>:<pages title="Pages" apt_id="716" id="pages_716">5376–88</pages>. <url title="URL" type="uri" href="https://doi.org/10.1128/MCB.15.10.5376" apt_id="717" id="url_717">https://doi.org/10.1128/MCB.15.10.5376</url> </jcit></bib><bib type="arabic" id="bib_718" sno="12" suffix="." apt_id="718"><jcit apt_id="719" id="jcit_719"><au apt_id="720" id="au_720"><s title="Surname" apt_id="721" id="s_721">Maheshri</s><f title="First name" apt_id="722" id="f_722">N</f></au>, <au apt_id="723" id="au_723"><s title="Surname" apt_id="724" id="s_724">Koerber</s><f title="First name" apt_id="725" id="f_725">JT</f></au>, <au apt_id="726" id="au_726"><s title="Surname" apt_id="727" id="s_727">Kaspar</s><f title="First name" apt_id="728" id="f_728">BK</f></au>, <etal title="etal" apt_id="729" id="etal_729">et al.</etal> <at title="Article Title" apt_id="730" id="at_730">Directed evolution of adeno-associated virus yields enhanced gene delivery vectors</at>. <pt title="Periodical Title" apt_id="731" id="pt_731">Nat Biotechnol</pt> <yr title="Year" apt_id="732" id="yr_732">2006</yr>;<v title="Volume" apt_id="733" id="v_733">24</v>:<pages title="Pages" apt_id="734" id="pages_734">198–204</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nbt1182" apt_id="735" id="url_735">https://doi.org/10.1038/nbt1182</url> </jcit></bib><bib type="arabic" id="bib_736" sno="13" suffix="." apt_id="736"><jcit apt_id="737" id="jcit_737"><au apt_id="738" id="au_738"><s title="Surname" apt_id="739" id="s_739">Merkle</s><f title="First name" apt_id="740" id="f_740">T</f></au>, <au apt_id="741" id="au_741"><s title="Surname" apt_id="742" id="s_742">Merz</s><f title="First name" apt_id="743" id="f_743">S</f></au>, <au apt_id="744" id="au_744"><s title="Surname" apt_id="745" id="s_745">Reautschnig</s><f title="First name" apt_id="746" id="f_746">P</f></au>, <etal title="etal" apt_id="747" id="etal_747">et al.</etal> <at title="Article Title" apt_id="748" id="at_748">Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides</at>. <pt title="Periodical Title" apt_id="749" id="pt_749">Nat Biotechnol</pt> <yr title="Year" apt_id="750" id="yr_750">2019</yr>;<v title="Volume" apt_id="751" id="v_751">37</v>:<pages title="Pages" apt_id="752" id="pages_752">133–8</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41587-019-0013-6" apt_id="753" id="url_753">https://doi.org/10.1038/s41587-019-0013-6</url> </jcit></bib><bib type="arabic" id="bib_754" sno="14" suffix="." apt_id="754"><jcit apt_id="755" id="jcit_755"><au apt_id="756" id="au_756"><s title="Surname" apt_id="757" id="s_757">Rees</s><f title="First name" apt_id="758" id="f_758">HA</f></au>, <au apt_id="759" id="au_759"><s title="Surname" apt_id="760" id="s_760">Liu</s><f title="First name" apt_id="761" id="f_761">DR.</f></au>, <at title="Article Title" apt_id="762" id="at_762">Base editing: precision chemistry on the genome and transcriptome of living cells</at>. <pt title="Periodical Title" apt_id="763" id="pt_763">Nat Rev Genet</pt> <yr title="Year" apt_id="764" id="yr_764">2018</yr>;<v title="Volume" apt_id="765" id="v_765">19</v>:<pages title="Pages" apt_id="766" id="pages_766">770–88</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41576-018-0059-1" apt_id="767" id="url_767">https://doi.org/10.1038/s41576-018-0059-1</url> </jcit></bib><bib type="arabic" id="bib_768" sno="15" suffix="." apt_id="768"><jcit apt_id="769" id="jcit_769"><au apt_id="770" id="au_770"><s title="Surname" apt_id="771" id="s_771">Porto</s><f title="First name" apt_id="772" id="f_772">EM</f></au>, <au apt_id="773" id="au_773"><s title="Surname" apt_id="774" id="s_774">Komor</s><f title="First name" apt_id="775" id="f_775">AC</f></au>, <au apt_id="776" id="au_776"><s title="Surname" apt_id="777" id="s_777">Slaymaker</s><f title="First name" apt_id="778" id="f_778">IM</f></au>, <etal title="etal" apt_id="779" id="etal_779">et al.</etal> <at title="Article Title" apt_id="780" id="at_780">Base editing: advances and therapeutic opportunities</at>. <pt title="Periodical Title" apt_id="781" id="pt_781">Nat Rev Drug Discov</pt> <yr title="Year" apt_id="782" id="yr_782">2020</yr>;<v title="Volume" apt_id="783" id="v_783">19</v>:<pages title="Pages" apt_id="784" id="pages_784">839–59</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41573-020-0084-6" apt_id="785" id="url_785">https://doi.org/10.1038/s41573-020-0084-6</url> </jcit></bib><bib type="arabic" id="bib_786" sno="16" suffix="." apt_id="786"><jcit apt_id="787" id="jcit_787"><au apt_id="788" id="au_788"><s title="Surname" apt_id="789" id="s_789">Pfeiffer</s><f title="First name" apt_id="790" id="f_790">LS</f></au>, <au apt_id="791" id="au_791"><s title="Surname" apt_id="792" id="s_792">Stafforst</s><f title="First name" apt_id="793" id="f_793">T</f></au>, . <at title="Article Title" apt_id="794" id="at_794">Precision RNA base editing with engineered and endogenous effectors</at>. <pt title="Periodical Title" apt_id="795" id="pt_795">Nat Biotechnol</pt> <yr title="Year" apt_id="796" id="yr_796">2023</yr>;<v title="Volume" apt_id="797" id="v_797">41</v>:<pages title="Pages" apt_id="798" id="pages_798">1526–42</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41587-023-01927-0" apt_id="799" id="url_799">https://doi.org/10.1038/s41587-023-01927-0</url> </jcit></bib><bib type="arabic" id="bib_800" sno="17" suffix="." apt_id="800"><jcit apt_id="801" id="jcit_801"><au apt_id="802" id="au_802"><s title="Surname" apt_id="803" id="s_803">Park</s><f title="First name" apt_id="804" id="f_804">S</f></au>, <au apt_id="805" id="au_805"><s title="Surname" apt_id="806" id="s_806">Beal</s><f title="First name" apt_id="807" id="f_807">PA</f></au>, . <at title="Article Title" apt_id="808" id="at_808">Off-target editing by CRISPR-guided DNA base editors</at>. <pt title="Periodical Title" apt_id="809" id="pt_809">Biochemistry</pt> <yr title="Year" apt_id="810" id="yr_810">2019</yr>;<v title="Volume" apt_id="811" id="v_811">58</v>:<pages title="Pages" apt_id="812" id="pages_812">3727–34</pages>. <url title="URL" type="uri" href="https://doi.org/10.1021/acs.biochem.9b00573" apt_id="813" id="url_813">https://doi.org/10.1021/acs.biochem.9b00573</url> </jcit></bib><bib type="arabic" id="bib_814" sno="18" suffix="." apt_id="814"><jcit apt_id="815" id="jcit_815"><au apt_id="816" id="au_816"><s title="Surname" apt_id="817" id="s_817">Gold</s><f title="First name" apt_id="818" id="f_818">A</f></au>, <au apt_id="819" id="au_819"><s title="Surname" apt_id="820" id="s_820">Levanon</s><f title="First name" apt_id="821" id="f_821">EY</f></au>, <au apt_id="822" id="au_822"><s title="Surname" apt_id="823" id="s_823">Eisenberg</s><f title="First name" apt_id="824" id="f_824">E</f></au>, . <at title="Article Title" apt_id="825" id="at_825">The new RNA-editing era – Ethical considerations</at>. <pt title="Periodical Title" apt_id="826" id="pt_826">Trends Genet</pt> <yr title="Year" apt_id="827" id="yr_827">2021</yr>;<v title="Volume" apt_id="828" id="v_828">37</v>:<pages title="Pages" apt_id="829" id="pages_829">685–7</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.tig.2021.04.013" apt_id="830" id="url_830">https://doi.org/10.1016/j.tig.2021.04.013</url> </jcit></bib><bib type="arabic" id="bib_831" sno="19" suffix="." apt_id="831"><jcit apt_id="832" id="jcit_832"><au apt_id="833" id="au_833"><s title="Surname" apt_id="834" id="s_834">Grünewald</s><f title="First name" apt_id="835" id="f_835">J</f></au>, <au apt_id="836" id="au_836"><s title="Surname" apt_id="837" id="s_837">Zhou</s><f title="First name" apt_id="838" id="f_838">R</f></au>, <au apt_id="839" id="au_839"><s title="Surname" apt_id="840" id="s_840">Garcia</s><f title="First name" apt_id="841" id="f_841">SP</f></au>, <etal title="etal" apt_id="842" id="etal_842">et al.</etal> <at title="Article Title" apt_id="843" id="at_843">Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors</at>. <pt title="Periodical Title" apt_id="844" id="pt_844">Nature</pt> <yr title="Year" apt_id="845" id="yr_845">2019</yr>;<v title="Volume" apt_id="846" id="v_846">569</v>:<pages title="Pages" apt_id="847" id="pages_847">433–7</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41586-019-1161-z" apt_id="848" id="url_848">https://doi.org/10.1038/s41586-019-1161-z</url> </jcit></bib><bib type="arabic" id="bib_849" sno="20" suffix="." apt_id="849"><jcit apt_id="850" id="jcit_850"><au apt_id="851" id="au_851"><s title="Surname" apt_id="852" id="s_852">Buchumenski</s><f title="First name" apt_id="853" id="f_853">I</f></au>, <au apt_id="854" id="au_854"><s title="Surname" apt_id="855" id="s_855">Roth</s><f title="First name" apt_id="856" id="f_856">SH</f></au>, <au apt_id="857" id="au_857"><s title="Surname" apt_id="858" id="s_858">Kopel</s><f title="First name" apt_id="859" id="f_859">E</f></au>, <etal title="etal" apt_id="860" id="etal_860">et al.</etal> <at title="Article Title" apt_id="861" id="at_861">Global quantification exposes abundant low-level off-target activity by base editors</at>. <pt title="Periodical Title" apt_id="862" id="pt_862">Genome Res</pt> <yr title="Year" apt_id="863" id="yr_863">2021</yr>;<v title="Volume" apt_id="864" id="v_864">31</v>:<pages title="Pages" apt_id="865" id="pages_865">2354–61</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gr.275770.121" apt_id="866" id="url_866">https://doi.org/10.1101/gr.275770.121</url> </jcit></bib><bib type="arabic" id="bib_867" sno="21" suffix="." apt_id="867"><jcit apt_id="868" id="jcit_868"><au apt_id="869" id="au_869"><s title="Surname" apt_id="870" id="s_870">Sinha</s><f title="First name" apt_id="871" id="f_871">S</f></au>, <au apt_id="872" id="au_872"><s title="Surname" apt_id="873" id="s_873">Barbosa</s><f title="First name" apt_id="874" id="f_874">K</f></au>, <au apt_id="875" id="au_875"><s title="Surname" apt_id="876" id="s_876">Cheng</s><f title="First name" apt_id="877" id="f_877">K</f></au>, <etal title="etal" apt_id="878" id="etal_878">et al.</etal> <at title="Article Title" apt_id="879" id="at_879">A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing</at>. <pt title="Periodical Title" apt_id="880" id="pt_880">Nat Commun</pt> <yr title="Year" apt_id="881" id="yr_881">2021</yr>;<v title="Volume" apt_id="882" id="v_882">12</v>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41467-021-26788-6" apt_id="883" id="url_883">https://doi.org/10.1038/s41467-021-26788-6</url><query><button type="button" title="Copy Editor to Author-AU: Pages is missing in this reference [21]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="23" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">23</span></button></query></jcit></bib><bib type="arabic" id="bib_886" sno="22" suffix="." apt_id="886"><jcit apt_id="887" id="jcit_887"><au apt_id="888" id="au_888"><s title="Surname" apt_id="889" id="s_889">Nahmad</s><f title="First name" apt_id="890" id="f_890">AD</f></au>, <au apt_id="891" id="au_891"><s title="Surname" apt_id="892" id="s_892">Reuveni</s><f title="First name" apt_id="893" id="f_893">E</f></au>, <au apt_id="894" id="au_894"><s title="Surname" apt_id="895" id="s_895">Goldschmidt</s><f title="First name" apt_id="896" id="f_896">E</f></au>, <etal title="etal" apt_id="897" id="etal_897">et al.</etal> <at title="Article Title" apt_id="898" id="at_898">Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage</at>. <pt title="Periodical Title" apt_id="899" id="pt_899">Nat Biotechnol</pt> <yr title="Year" apt_id="900" id="yr_900">2022</yr>;<v title="Volume" apt_id="901" id="v_901">40</v>:<pages title="Pages" apt_id="902" id="pages_902">1807–13</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41587-022-01377-0" apt_id="903" id="url_903">https://doi.org/10.1038/s41587-022-01377-0</url> </jcit></bib><bib type="arabic" id="bib_904" sno="23" suffix="." apt_id="904"><jcit apt_id="905" id="jcit_905"><au apt_id="906" id="au_906"><s title="Surname" apt_id="907" id="s_907">Hsiao</s><f title="First name" apt_id="908" id="f_908">YHE</f></au>, <au apt_id="909" id="au_909"><s title="Surname" apt_id="910" id="s_910">Bahn</s><f title="First name" apt_id="911" id="f_911">JH</f></au>, <au apt_id="912" id="au_912"><s title="Surname" apt_id="913" id="s_913">Yang</s><f title="First name" apt_id="914" id="f_914">Y</f></au>, <etal title="etal" apt_id="915" id="etal_915">et al.</etal> <at title="Article Title" apt_id="916" id="at_916">RNA editing in nascent RNA affects pre-mRNA splicing</at>. <pt title="Periodical Title" apt_id="917" id="pt_917">Genome Res</pt> <yr title="Year" apt_id="918" id="yr_918">2018</yr>;<v title="Volume" apt_id="919" id="v_919">28</v>:<pages title="Pages" apt_id="920" id="pages_920">812–23</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gr.231209.117" apt_id="921" id="url_921">https://doi.org/10.1101/gr.231209.117</url> </jcit></bib><bib type="arabic" id="bib_922" sno="24" suffix="." apt_id="922"><jcit apt_id="923" id="jcit_923"><au apt_id="924" id="au_924"><s title="Surname" apt_id="925" id="s_925">Paz-Yaacov</s><f title="First name" apt_id="926" id="f_926">N</f></au>, <au apt_id="927" id="au_927"><s title="Surname" apt_id="928" id="s_928">Bazak</s><f title="First name" apt_id="929" id="f_929">L</f></au>, <au apt_id="930" id="au_930"><s title="Surname" apt_id="931" id="s_931">Buchumenski</s><f title="First name" apt_id="932" id="f_932">I</f></au>, <etal title="etal" apt_id="933" id="etal_933">et al.</etal> <at title="Article Title" apt_id="934" id="at_934">Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors</at>. <pt title="Periodical Title" apt_id="935" id="pt_935">Cell Rep</pt> <yr title="Year" apt_id="936" id="yr_936">2015</yr>;<v title="Volume" apt_id="937" id="v_937">13</v>:<pages title="Pages" apt_id="938" id="pages_938">267–76</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.celrep.2015.08.080" apt_id="939" id="url_939">https://doi.org/10.1016/j.celrep.2015.08.080</url> </jcit></bib><bib type="arabic" id="bib_940" sno="25" suffix="." apt_id="940"><jcit apt_id="941" id="jcit_941"><au apt_id="942" id="au_942"><s title="Surname" apt_id="943" id="s_943">Garber</s><f title="First name" apt_id="944" id="f_944">JE</f></au>, <au apt_id="945" id="au_945"><s title="Surname" apt_id="946" id="s_946">Offit</s><f title="First name" apt_id="947" id="f_947">K</f></au>, . <at title="Article Title" apt_id="948" id="at_948">Hereditary cancer predisposition syndromes</at>. <pt title="Periodical Title" apt_id="949" id="pt_949">JCO</pt> <yr title="Year" apt_id="950" id="yr_950">2005</yr>;<v title="Volume" apt_id="951" id="v_951">23</v>:<pages title="Pages" apt_id="952" id="pages_952">276–92</pages>. <url title="URL" type="uri" href="https://doi.org/10.1200/JCO.2005.10.042" apt_id="953" id="url_953">https://doi.org/10.1200/JCO.2005.10.042</url></jcit></bib><bib type="arabic" id="bib_954" sno="26" suffix="." apt_id="954"><jcit apt_id="955" id="jcit_955"><au apt_id="956" id="au_956"><s title="Surname" apt_id="957" id="s_957">Landrum</s><f title="First name" apt_id="958" id="f_958">MJ</f></au>, <au apt_id="959" id="au_959"><s title="Surname" apt_id="960" id="s_960">Lee</s><f title="First name" apt_id="961" id="f_961">JM</f></au>, <au apt_id="962" id="au_962"><s title="Surname" apt_id="963" id="s_963">Benson</s><f title="First name" apt_id="964" id="f_964">M</f></au>, <etal title="etal" apt_id="965" id="etal_965">et al.</etal> <at title="Article Title" apt_id="966" id="at_966">ClinVar: improving access to variant interpretations and supporting evidence</at>. <pt title="Periodical Title" apt_id="967" id="pt_967">Nucleic Acids Res</pt> <yr title="Year" apt_id="968" id="yr_968">2018</yr>;<v title="Volume" apt_id="969" id="v_969">46</v>:<pages title="Pages" apt_id="970" id="pages_970">D1062–7</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gkx1153" apt_id="971" id="url_971">https://doi.org/10.1093/nar/gkx1153</url> </jcit></bib><bib type="arabic" id="bib_972" sno="27" suffix="." apt_id="972"><jcit apt_id="973" id="jcit_973"><au apt_id="974" id="au_974"><s title="Surname" apt_id="975" id="s_975">Kent</s><f title="First name" apt_id="976" id="f_976">WJ</f></au>, <au apt_id="977" id="au_977"><s title="Surname" apt_id="978" id="s_978">Sugnet</s><f title="First name" apt_id="979" id="f_979">CW</f></au>, <au apt_id="980" id="au_980"><s title="Surname" apt_id="981" id="s_981">Furey</s><f title="First name" apt_id="982" id="f_982">TS</f></au>, <etal title="etal" apt_id="983" id="etal_983">et al.</etal> <at title="Article Title" apt_id="984" id="at_984">The Human genome browser at UCSC</at>. <pt title="Periodical Title" apt_id="985" id="pt_985">Genome Res</pt> <yr title="Year" apt_id="986" id="yr_986">2002</yr>;<v title="Volume" apt_id="987" id="v_987">12</v>:<pages title="Pages" apt_id="988" id="pages_988">996–1006</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gr.229102" apt_id="989" id="url_989">https://doi.org/10.1101/gr.229102</url> </jcit></bib><bib type="arabic" id="bib_990" sno="28" suffix="." apt_id="990"><othcit exinfo="other" apt_id="991" id="othcit_991"><collab title="Collaborator" exinfo="author" apt_id="992" id="collab_992">Pediatric Cancer Panel</collab>. <yr title="Year" apt_id="993" id="yr_993">2023</yr>; <i apt_id="994" id="i_994"><url title="URL" type="uri" href="https://www.ncbi.nlm.nih.gov/gtr/tests/562503/" apt_id="995" id="url_995">https://www.ncbi.nlm.nih.gov/gtr/tests/562503/</url></i>. <misc1 title="Misc Text" apt_id="996" id="misc1_996">Last accessed date March-13-2025</misc1>.</othcit></bib><bib type="arabic" id="bib_997" sno="29" suffix="." apt_id="997"><othcit exinfo="other" apt_id="998" id="othcit_998"><collab title="Collaborator" exinfo="author" apt_id="999" id="collab_999">MedGen</collab>. <yr title="Year" apt_id="1000" id="yr_1000">2023</yr>; <i apt_id="1001" id="i_1001"><url title="URL" type="uri" href="https://www.ncbi.nlm.nih.gov/medgen/" apt_id="1002" id="url_1002">https://www.ncbi.nlm.nih.gov/medgen/</url></i>. <misc1 title="Misc Text" apt_id="1003" id="misc1_1003">Last accessed date March-13-2025</misc1>.</othcit></bib><bib type="arabic" id="bib_1004" sno="30" suffix="." apt_id="1004"><jcit apt_id="1005" id="jcit_1005"><au apt_id="1006" id="au_1006"><s title="Surname" apt_id="1007" id="s_1007">Srinivasan</s><f title="First name" apt_id="1008" id="f_1008">P</f></au>, <au apt_id="1009" id="au_1009"><s title="Surname" apt_id="1010" id="s_1010">Bandlamudi</s><f title="First name" apt_id="1011" id="f_1011">C</f></au>, <au apt_id="1012" id="au_1012"><s title="Surname" apt_id="1013" id="s_1013">Jonsson</s><f title="First name" apt_id="1014" id="f_1014">P</f></au>, <etal title="etal" apt_id="1015" id="etal_1015">et al.</etal> <at title="Article Title" apt_id="1016" id="at_1016">The context-specific role of germline pathogenicity in tumorigenesis</at>. <pt title="Periodical Title" apt_id="1017" id="pt_1017">Nat Genet</pt> <yr title="Year" apt_id="1018" id="yr_1018">2021</yr>;<v title="Volume" apt_id="1019" id="v_1019">53</v>:<pages title="Pages" apt_id="1020" id="pages_1020">1577–85</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41588-021-00949-1" apt_id="1021" id="url_1021">https://doi.org/10.1038/s41588-021-00949-1</url> </jcit></bib><bib type="arabic" id="bib_1022" sno="31" suffix="." apt_id="1022"><jcit apt_id="1023" id="jcit_1023"><au apt_id="1024" id="au_1024"><s title="Surname" apt_id="1025" id="s_1025">Kent</s><f title="First name" apt_id="1026" id="f_1026">WJ</f></au>, . <at title="Article Title" apt_id="1027" id="at_1027">BLAT—The BLAST-like alignment tool</at>. <pt title="Periodical Title" apt_id="1028" id="pt_1028">Genome Res</pt> <yr title="Year" apt_id="1029" id="yr_1029">2002</yr>;<v title="Volume" apt_id="1030" id="v_1030">12</v>:<pages title="Pages" apt_id="1031" id="pages_1031">656–64</pages>. </jcit></bib><bib type="arabic" id="bib_1032" sno="32" suffix="." apt_id="1032"><jcit apt_id="1033" id="jcit_1033"><au apt_id="1034" id="au_1034"><s title="Surname" apt_id="1035" id="s_1035">Cheng</s><f title="First name" apt_id="1036" id="f_1036">J</f></au>, <au apt_id="1037" id="au_1037"><s title="Surname" apt_id="1038" id="s_1038">Novati</s><f title="First name" apt_id="1039" id="f_1039">G</f></au>, <au apt_id="1040" id="au_1040"><s title="Surname" apt_id="1041" id="s_1041">Pan</s><f title="First name" apt_id="1042" id="f_1042">J</f></au>, <etal title="etal" apt_id="1043" id="etal_1043">et al.</etal> <at title="Article Title" apt_id="1044" id="at_1044">Accurate proteome-wide missense variant effect prediction with AlphaMissense</at>. <pt title="Periodical Title" apt_id="1045" id="pt_1045">Science</pt> <yr title="Year" apt_id="1046" id="yr_1046">2023</yr>;<v title="Volume" apt_id="1047" id="v_1047">381</v>. <url title="URL" type="uri" href="https://doi.org/10.1126/science.adg7492" apt_id="1048" id="url_1048">https://doi.org/10.1126/science.adg7492</url><query><button type="button" title="Copy Editor to Author-AU: Pages is missing in this reference [32]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="24" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">24</span></button></query></jcit></bib><bib type="arabic" id="bib_1051" sno="33" suffix="." apt_id="1051"><jcit apt_id="1052" id="jcit_1052"><au apt_id="1053" id="au_1053"><s title="Surname" apt_id="1054" id="s_1054">Reautschnig</s><f title="First name" apt_id="1055" id="f_1055">P</f></au>, <au apt_id="1056" id="au_1056"><s title="Surname" apt_id="1057" id="s_1057">Wahn</s><f title="First name" apt_id="1058" id="f_1058">N</f></au>, <au apt_id="1059" id="au_1059"><s title="Surname" apt_id="1060" id="s_1060">Wettengel</s><f title="First name" apt_id="1061" id="f_1061">J</f></au>, <etal title="etal" apt_id="1062" id="etal_1062">et al.</etal> <at title="Article Title" apt_id="1063" id="at_1063">CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo</at>. <pt title="Periodical Title" apt_id="1064" id="pt_1064">Nat Biotechnol</pt> <yr title="Year" apt_id="1065" id="yr_1065">2022</yr>;<url title="URL" type="uri" href="https://doi.org/10.1038/s41587-021-01105-0" apt_id="1066" id="url_1066">https://doi.org/10.1038/s41587-021-01105-0</url> <query><button type="button" title="Copy Editor to Author-AU: Volume and Pages are missing in this reference [33]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="25" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">25</span></button></query></jcit></bib><bib type="arabic" id="bib_1069" sno="34" suffix="." apt_id="1069"><jcit apt_id="1070" id="jcit_1070"><au apt_id="1071" id="au_1071"><s title="Surname" apt_id="1072" id="s_1072">Qu</s><f title="First name" apt_id="1073" id="f_1073">L</f></au>, <au apt_id="1074" id="au_1074"><s title="Surname" apt_id="1075" id="s_1075">Yi</s><f title="First name" apt_id="1076" id="f_1076">Z</f></au>, <au apt_id="1077" id="au_1077"><s title="Surname" apt_id="1078" id="s_1078">Zhu</s><f title="First name" apt_id="1079" id="f_1079">S</f></au>, <etal title="etal" apt_id="1080" id="etal_1080">et al.</etal> <at title="Article Title" apt_id="1081" id="at_1081">Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs</at>. <pt title="Periodical Title" apt_id="1082" id="pt_1082">Nat Biotechnol</pt> <yr title="Year" apt_id="1083" id="yr_1083">2019</yr>;<v title="Volume" apt_id="1084" id="v_1084">37</v>:<pages title="Pages" apt_id="1085" id="pages_1085">1059–69</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41587-019-0178-z" apt_id="1086" id="url_1086">https://doi.org/10.1038/s41587-019-0178-z</url> </jcit></bib><bib type="arabic" id="bib_1087" sno="35" suffix="." apt_id="1087"><jcit apt_id="1088" id="jcit_1088"><au apt_id="1089" id="au_1089"><s title="Surname" apt_id="1090" id="s_1090">Karczewski</s><f title="First name" apt_id="1091" id="f_1091">KJ</f></au>, <au apt_id="1092" id="au_1092"><s title="Surname" apt_id="1093" id="s_1093">Francioli</s><f title="First name" apt_id="1094" id="f_1094">LC</f></au>, <au apt_id="1095" id="au_1095"><s title="Surname" apt_id="1096" id="s_1096">Tiao</s><f title="First name" apt_id="1097" id="f_1097">G</f></au>, <etal title="etal" apt_id="1098" id="etal_1098">et al.</etal> <at title="Article Title" apt_id="1099" id="at_1099">The mutational constraint spectrum quantified from variation in 141,456 humans</at>. <pt title="Periodical Title" apt_id="1100" id="pt_1100">Nature</pt> <yr title="Year" apt_id="1101" id="yr_1101">2020</yr>;<v title="Volume" apt_id="1102" id="v_1102">581</v>:<pages title="Pages" apt_id="1103" id="pages_1103">434–43</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41586-020-2308-7" apt_id="1104" id="url_1104">https://doi.org/10.1038/s41586-020-2308-7</url> </jcit></bib><bib type="arabic" id="bib_1105" sno="36" suffix="." apt_id="1105"><jcit apt_id="1106" id="jcit_1106"><au apt_id="1107" id="au_1107"><s title="Surname" apt_id="1108" id="s_1108">Gudmundsson</s><f title="First name" apt_id="1109" id="f_1109">S</f></au>, <au apt_id="1110" id="au_1110"><s title="Surname" apt_id="1111" id="s_1111">Singer-Berk</s><f title="First name" apt_id="1112" id="f_1112">M</f></au>, <au apt_id="1113" id="au_1113"><s title="Surname" apt_id="1114" id="s_1114">Watts</s><f title="First name" apt_id="1115" id="f_1115">NA</f></au>, <etal title="etal" apt_id="1116" id="etal_1116">et al.</etal> <at title="Article Title" apt_id="1117" id="at_1117">Variant interpretation using population databases: lessons from gnomAD</at>. <pt title="Periodical Title" apt_id="1118" id="pt_1118">Hum Mutat</pt> <yr title="Year" apt_id="1119" id="yr_1119">2022</yr>;<v title="Volume" apt_id="1120" id="v_1120">43</v>:<pages title="Pages" apt_id="1121" id="pages_1121">1012–30</pages>. <url title="URL" type="uri" href="https://doi.org/10.1002/humu.24309" apt_id="1122" id="url_1122">https://doi.org/10.1002/humu.24309</url> </jcit></bib><bib type="arabic" id="bib_1123" sno="37" suffix="." apt_id="1123"><jcit apt_id="1124" id="jcit_1124"><au apt_id="1125" id="au_1125"><s title="Surname" apt_id="1126" id="s_1126">Campbell</s><f title="First name" apt_id="1127" id="f_1127">PJ</f></au>, <au apt_id="1128" id="au_1128"><s title="Surname" apt_id="1129" id="s_1129">Getz</s><f title="First name" apt_id="1130" id="f_1130">G</f></au>, <au apt_id="1131" id="au_1131"><s title="Surname" apt_id="1132" id="s_1132">Korbel</s><f title="First name" apt_id="1133" id="f_1133">JO</f></au>, <etal title="etal" apt_id="1134" id="etal_1134">et al.</etal> <at title="Article Title" apt_id="1135" id="at_1135">Pan-cancer analysis of whole genomes</at>. <pt title="Periodical Title" apt_id="1136" id="pt_1136">Nature</pt> <yr title="Year" apt_id="1137" id="yr_1137">2020</yr>;<v title="Volume" apt_id="1138" id="v_1138">578</v>:<pages title="Pages" apt_id="1139" id="pages_1139">82–93</pages>. </jcit></bib><bib type="arabic" id="bib_1140" sno="38" suffix="." apt_id="1140"><jcit apt_id="1141" id="jcit_1141"><au apt_id="1142" id="au_1142"><s title="Surname" apt_id="1143" id="s_1143">Suehnholz</s><f title="First name" apt_id="1144" id="f_1144">SP</f></au>, <au apt_id="1145" id="au_1145"><s title="Surname" apt_id="1146" id="s_1146">Nissan</s><f title="First name" apt_id="1147" id="f_1147">MH</f></au>, <au apt_id="1148" id="au_1148"><s title="Surname" apt_id="1149" id="s_1149">Zhang</s><f title="First name" apt_id="1150" id="f_1150">H</f></au>, <etal title="etal" apt_id="1151" id="etal_1151">et al.</etal> <at title="Article Title" apt_id="1152" id="at_1152">Quantifying the expanding landscape of clinical actionability for patients with cancer</at>. <pt title="Periodical Title" apt_id="1153" id="pt_1153">Cancer Discov</pt> <yr title="Year" apt_id="1154" id="yr_1154">2024</yr>;<v title="Volume" apt_id="1155" id="v_1155">14</v>:<pages title="Pages" apt_id="1156" id="pages_1156">49–65</pages>. <url title="URL" type="uri" href="https://doi.org/10.1158/2159-8290.CD-23-0467" apt_id="1157" id="url_1157">https://doi.org/10.1158/2159-8290.CD-23-0467</url> </jcit></bib><bib type="arabic" id="bib_1158" sno="39" suffix="." apt_id="1158"><jcit apt_id="1159" id="jcit_1159"><au apt_id="1160" id="au_1160"><s title="Surname" apt_id="1161" id="s_1161">Geary</s><f title="First name" apt_id="1162" id="f_1162">RS</f></au>, <au apt_id="1163" id="au_1163"><s title="Surname" apt_id="1164" id="s_1164">Norris</s><f title="First name" apt_id="1165" id="f_1165">D</f></au>, <au apt_id="1166" id="au_1166"><s title="Surname" apt_id="1167" id="s_1167">Yu</s><f title="First name" apt_id="1168" id="f_1168">R</f></au>, <etal title="etal" apt_id="1169" id="etal_1169">et al.</etal> <at title="Article Title" apt_id="1170" id="at_1170">Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides</at>. <pt title="Periodical Title" apt_id="1171" id="pt_1171">Adv Drug Deliv Rev</pt> <yr title="Year" apt_id="1172" id="yr_1172">2015</yr>;<v title="Volume" apt_id="1173" id="v_1173">87</v>:<pages title="Pages" apt_id="1174" id="pages_1174">46–51</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.addr.2015.01.008" apt_id="1175" id="url_1175">https://doi.org/10.1016/j.addr.2015.01.008</url> </jcit></bib><bib type="arabic" id="bib_1176" sno="40" suffix="." apt_id="1176"><jcit apt_id="1177" id="jcit_1177"><au apt_id="1178" id="au_1178"><s title="Surname" apt_id="1179" id="s_1179">Fearon</s><f title="First name" apt_id="1180" id="f_1180">EF</f></au>, <au apt_id="1181" id="au_1181"><s title="Surname" apt_id="1182" id="s_1182">Vogelstein</s><f title="First name" apt_id="1183" id="f_1183">B</f></au>, . <at title="Article Title" apt_id="1184" id="at_1184">A genetic model for colorectal tumorigenesis</at>. <pt title="Periodical Title" apt_id="1185" id="pt_1185">Cell</pt> <yr title="Year" apt_id="1186" id="yr_1186">1990</yr>;<v title="Volume" apt_id="1187" id="v_1187">61</v>:<pages title="Pages" apt_id="1188" id="pages_1188">759–67</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/0092-8674(90)90186-I" apt_id="1189" id="url_1189">https://doi.org/10.1016/0092-8674(90)90186-I</url> </jcit></bib><bib type="arabic" id="bib_1190" sno="41" suffix="." apt_id="1190"><jcit apt_id="1191" id="jcit_1191"><au apt_id="1192" id="au_1192"><s title="Surname" apt_id="1193" id="s_1193">Freed-Pastor</s><f title="First name" apt_id="1194" id="f_1194">WA</f></au>, <au apt_id="1195" id="au_1195"><s title="Surname" apt_id="1196" id="s_1196">Prives</s><f title="First name" apt_id="1197" id="f_1197">C</f></au>, . <at title="Article Title" apt_id="1198" id="at_1198">Mutant p53: one name, many proteins</at>. <pt title="Periodical Title" apt_id="1199" id="pt_1199">Genes Dev</pt> <yr title="Year" apt_id="1200" id="yr_1200">2012</yr>;<v title="Volume" apt_id="1201" id="v_1201">26</v>:<pages title="Pages" apt_id="1202" id="pages_1202">1268–86</pages>. <url title="URL" type="uri" href="https://doi.org/10.1101/gad.190678.112" apt_id="1203" id="url_1203">https://doi.org/10.1101/gad.190678.112</url> </jcit></bib><bib type="arabic" id="bib_1204" sno="42" suffix="." apt_id="1204"><jcit apt_id="1205" id="jcit_1205"><au apt_id="1206" id="au_1206"><s title="Surname" apt_id="1207" id="s_1207">Guha</s><f title="First name" apt_id="1208" id="f_1208">T</f></au>, <au apt_id="1209" id="au_1209"><s title="Surname" apt_id="1210" id="s_1210">Malkin</s><f title="First name" apt_id="1211" id="f_1211">D</f></au>, . <at title="Article Title" apt_id="1212" id="at_1212">Inherited TP53 mutations and the Li–Fraumeni syndrome</at>. <pt title="Periodical Title" apt_id="1213" id="pt_1213">Cold Spring Harb Perspect Med</pt> <yr title="Year" apt_id="1214" id="yr_1214">2017</yr>;<v title="Volume" apt_id="1215" id="v_1215">7</v>. <url title="URL" type="uri" href="https://doi.org/10.1101/cshperspect.a026187" apt_id="1216" id="url_1216">https://doi.org/10.1101/cshperspect.a026187</url> <query><button type="button" title="Copy Editor to Author-AU: Pages is missing in this reference [42]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="26" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">26</span></button></query></jcit></bib><bib type="arabic" id="bib_1219" sno="43" suffix="." apt_id="1219"><jcit apt_id="1220" id="jcit_1220"><au apt_id="1221" id="au_1221"><s title="Surname" apt_id="1222" id="s_1222">Grossman</s><f title="First name" apt_id="1223" id="f_1223">RL</f></au>, <au apt_id="1224" id="au_1224"><s title="Surname" apt_id="1225" id="s_1225">Heath</s><f title="First name" apt_id="1226" id="f_1226">AP</f></au>, <au apt_id="1227" id="au_1227"><s title="Surname" apt_id="1228" id="s_1228">Ferretti</s><f title="First name" apt_id="1229" id="f_1229">V</f></au>, <etal title="etal" apt_id="1230" id="etal_1230">et al.</etal> <at title="Article Title" apt_id="1231" id="at_1231">Toward a shared vision for cancer genomic data</at>. <pt title="Periodical Title" apt_id="1232" id="pt_1232">N Engl J Med</pt> <yr title="Year" apt_id="1233" id="yr_1233">2016</yr>;<v title="Volume" apt_id="1234" id="v_1234">375</v>:<pages title="Pages" apt_id="1235" id="pages_1235">1109–12</pages>. <url title="URL" type="uri" href="https://doi.org/10.1056/NEJMp1607591" apt_id="1236" id="url_1236">https://doi.org/10.1056/NEJMp1607591</url> </jcit></bib><bib type="arabic" id="bib_1237" sno="44" suffix="." apt_id="1237"><jcit apt_id="1238" id="jcit_1238"><au apt_id="1239" id="au_1239"><s title="Surname" apt_id="1240" id="s_1240">Chiang</s><f title="First name" apt_id="1241" id="f_1241">Y-T</f></au>, <au apt_id="1242" id="au_1242"><s title="Surname" apt_id="1243" id="s_1243">Chien</s><f title="First name" apt_id="1244" id="f_1244">Y-C</f></au>, <au apt_id="1245" id="au_1245"><s title="Surname" apt_id="1246" id="s_1246">Lin</s><f title="First name" apt_id="1247" id="f_1247">Y-H</f></au>, <etal title="etal" apt_id="1248" id="etal_1248">et al.</etal> <at title="Article Title" apt_id="1249" id="at_1249">The function of the mutant p53-R175H in cancer</at>. <pt title="Periodical Title" apt_id="1250" id="pt_1250">Cancers</pt> <yr title="Year" apt_id="1251" id="yr_1251">2021</yr>;<v title="Volume" apt_id="1252" id="v_1252">13</v>:<pages title="Pages" apt_id="1253" id="pages_1253">4088</pages>. <url title="URL" type="uri" href="https://doi.org/10.3390/cancers13164088" apt_id="1254" id="url_1254">https://doi.org/10.3390/cancers13164088</url> </jcit></bib><bib type="arabic" id="bib_1255" sno="45" suffix="." apt_id="1255"><jcit apt_id="1256" id="jcit_1256"><au apt_id="1257" id="au_1257"><s title="Surname" apt_id="1258" id="s_1258">Nakayama</s><f title="First name" apt_id="1259" id="f_1259">M</f></au>, <au apt_id="1260" id="au_1260"><s title="Surname" apt_id="1261" id="s_1261">Oshima</s><f title="First name" apt_id="1262" id="f_1262">M</f></au>, . <at title="Article Title" apt_id="1263" id="at_1263">Mutant p53 in colon cancer</at>. <pt title="Periodical Title" apt_id="1264" id="pt_1264">J Mol Cell Biol</pt> <yr title="Year" apt_id="1265" id="yr_1265">2019</yr>;<v title="Volume" apt_id="1266" id="v_1266">11</v>:<pages title="Pages" apt_id="1267" id="pages_1267">267–76</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/jmcb/mjy075" apt_id="1268" id="url_1268">https://doi.org/10.1093/jmcb/mjy075</url> </jcit></bib><bib type="arabic" id="bib_1269" sno="46" suffix="." apt_id="1269"><jcit apt_id="1270" id="jcit_1270"><au apt_id="1271" id="au_1271"><s title="Surname" apt_id="1272" id="s_1272">Yan</s><f title="First name" apt_id="1273" id="f_1273">H</f></au>, <au apt_id="1274" id="au_1274"><s title="Surname" apt_id="1275" id="s_1275">Parsons</s><f title="First name" apt_id="1276" id="f_1276">DW</f></au>, <au apt_id="1277" id="au_1277"><s title="Surname" apt_id="1278" id="s_1278">Jin</s><f title="First name" apt_id="1279" id="f_1279">G</f></au>, <etal title="etal" apt_id="1280" id="etal_1280">et al.</etal> <at title="Article Title" apt_id="1281" id="at_1281">IDH1 and IDH2 mutations in gliomas</at>. <pt title="Periodical Title" apt_id="1282" id="pt_1282">N Engl J Med</pt> <yr title="Year" apt_id="1283" id="yr_1283">2009</yr>;<v title="Volume" apt_id="1284" id="v_1284">360</v>:<pages title="Pages" apt_id="1285" id="pages_1285">765–73</pages>. <url title="URL" type="uri" href="https://doi.org/10.1056/NEJMoa0808710" apt_id="1286" id="url_1286">https://doi.org/10.1056/NEJMoa0808710</url> </jcit></bib><bib type="arabic" id="bib_1287" sno="47" suffix="." apt_id="1287"><jcit apt_id="1288" id="jcit_1288"><au apt_id="1289" id="au_1289"><s title="Surname" apt_id="1290" id="s_1290">Han</s><f title="First name" apt_id="1291" id="f_1291">S</f></au>, <au apt_id="1292" id="au_1292"><s title="Surname" apt_id="1293" id="s_1293">Liu</s><f title="First name" apt_id="1294" id="f_1294">Y</f></au>, <au apt_id="1295" id="au_1295"><s title="Surname" apt_id="1296" id="s_1296">Cai</s><f title="First name" apt_id="1297" id="f_1297">SJ</f></au>, <etal title="etal" apt_id="1298" id="etal_1298">et al.</etal> <at title="Article Title" apt_id="1299" id="at_1299">IDH mutation in glioma: molecular mechanisms and potential therapeutic targets</at>. <pt title="Periodical Title" apt_id="1300" id="pt_1300">Br J Cancer</pt> <yr title="Year" apt_id="1301" id="yr_1301">2020</yr>;<v title="Volume" apt_id="1302" id="v_1302">122</v>:<pages title="Pages" apt_id="1303" id="pages_1303">1580–9</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41416-020-0814-x" apt_id="1304" id="url_1304">https://doi.org/10.1038/s41416-020-0814-x</url> </jcit></bib><bib type="arabic" id="bib_1305" sno="48" suffix="." apt_id="1305"><jcit apt_id="1306" id="jcit_1306"><au apt_id="1307" id="au_1307"><s title="Surname" apt_id="1308" id="s_1308">Huang</s><f title="First name" apt_id="1309" id="f_1309">L</f></au>, <au apt_id="1310" id="au_1310"><s title="Surname" apt_id="1311" id="s_1311">Guo</s><f title="First name" apt_id="1312" id="f_1312">Z</f></au>, <au apt_id="1313" id="au_1313"><s title="Surname" apt_id="1314" id="s_1314">Wang</s><f title="First name" apt_id="1315" id="f_1315">F</f></au>, <etal title="etal" apt_id="1316" id="etal_1316">et al.</etal> <at title="Article Title" apt_id="1317" id="at_1317">KRAS mutation: from undruggable to druggable in cancer</at>. <pt title="Periodical Title" apt_id="1318" id="pt_1318">Signal Transduct Target Ther</pt> <yr title="Year" apt_id="1319" id="yr_1319">2021</yr>;<v title="Volume" apt_id="1320" id="v_1320">6</v>.<query><button type="button" title="Copy Editor to Author-AU: Pages is missing in this reference [48]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="27" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">27</span></button></query></jcit></bib><bib type="arabic" id="bib_1323" sno="49" suffix="." apt_id="1323"><jcit apt_id="1324" id="jcit_1324"><au apt_id="1325" id="au_1325"><s title="Surname" apt_id="1326" id="s_1326">Lu</s><f title="First name" apt_id="1327" id="f_1327">S</f></au>, <au apt_id="1328" id="au_1328"><s title="Surname" apt_id="1329" id="s_1329">Jang</s><f title="First name" apt_id="1330" id="f_1330">H</f></au>, <au apt_id="1331" id="au_1331"><s title="Surname" apt_id="1332" id="s_1332">Nussinov</s><f title="First name" apt_id="1333" id="f_1333">R</f></au>, <etal title="etal" apt_id="1334" id="etal_1334">et al.</etal> <at title="Article Title" apt_id="1335" id="at_1335">The structural basis of oncogenic mutations G12, G13 and Q61 in small GTPase K-Ras4B</at>. <pt title="Periodical Title" apt_id="1336" id="pt_1336">Sci Rep</pt> <yr title="Year" apt_id="1337" id="yr_1337">2016</yr>;<v title="Volume" apt_id="1338" id="v_1338">6</v>:<pages title="Pages" apt_id="1339" id="pages_1339">1–15</pages>. </jcit></bib><bib type="arabic" id="bib_1340" sno="50" suffix="." apt_id="1340"><jcit apt_id="1341" id="jcit_1341"><au apt_id="1342" id="au_1342"><s title="Surname" apt_id="1343" id="s_1343">Hallin</s><f title="First name" apt_id="1344" id="f_1344">J</f></au>, <au apt_id="1345" id="au_1345"><s title="Surname" apt_id="1346" id="s_1346">Bowcut</s><f title="First name" apt_id="1347" id="f_1347">V</f></au>, <au apt_id="1348" id="au_1348"><s title="Surname" apt_id="1349" id="s_1349">Calinisan</s><f title="First name" apt_id="1350" id="f_1350">A</f></au>, <etal title="etal" apt_id="1351" id="etal_1351">et al.</etal> <at title="Article Title" apt_id="1352" id="at_1352">Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor</at>. <pt title="Periodical Title" apt_id="1353" id="pt_1353">Nat Med</pt> <yr title="Year" apt_id="1354" id="yr_1354">2022</yr>;<v title="Volume" apt_id="1355" id="v_1355">28</v>:<pages title="Pages" apt_id="1356" id="pages_1356">2171–82</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41591-022-02007-7" apt_id="1357" id="url_1357">https://doi.org/10.1038/s41591-022-02007-7</url> </jcit></bib><bib type="arabic" id="bib_1358" sno="51" suffix="." apt_id="1358"><jcit apt_id="1359" id="jcit_1359"><au apt_id="1360" id="au_1360"><s title="Surname" apt_id="1361" id="s_1361">Guevara</s><f title="First name" apt_id="1362" id="f_1362">ML</f></au>, <au apt_id="1363" id="au_1363"><s title="Surname" apt_id="1364" id="s_1364">Persano</s><f title="First name" apt_id="1365" id="f_1365">F</f></au>, <au apt_id="1366" id="au_1366"><s title="Surname" apt_id="1367" id="s_1367">Persano</s><f title="First name" apt_id="1368" id="f_1368">S</f></au>, . <at title="Article Title" apt_id="1369" id="at_1369">Advances in lipid nanoparticles for mRNA-based cancer immunotherapy</at>. <pt title="Periodical Title" apt_id="1370" id="pt_1370">Front Chem</pt> <yr title="Year" apt_id="1371" id="yr_1371">2020</yr>;<v title="Volume" apt_id="1372" id="v_1372">8</v>:<pages title="Pages" apt_id="1373" id="pages_1373">589959</pages>. <url title="URL" type="uri" href="https://doi.org/10.3389/fchem.2020.589959" apt_id="1374" id="url_1374">https://doi.org/10.3389/fchem.2020.589959</url> </jcit></bib><bib type="arabic" id="bib_1375" sno="52" suffix="." apt_id="1375"><jcit apt_id="1376" id="jcit_1376"><au apt_id="1377" id="au_1377"><s title="Surname" apt_id="1378" id="s_1378">Martincorena</s><f title="First name" apt_id="1379" id="f_1379">I</f></au>, <au apt_id="1380" id="au_1380"><s title="Surname" apt_id="1381" id="s_1381">Roshan</s><f title="First name" apt_id="1382" id="f_1382">A</f></au>, <au apt_id="1383" id="au_1383"><s title="Surname" apt_id="1384" id="s_1384">Gerstung</s><f title="First name" apt_id="1385" id="f_1385">M</f></au>, <etal title="etal" apt_id="1386" id="etal_1386">et al.</etal> <at title="Article Title" apt_id="1387" id="at_1387">High burden and pervasive positive selection of somatic mutations in normal human skin</at>. <pt title="Periodical Title" apt_id="1388" id="pt_1388">Science (1979)</pt> <yr title="Year" apt_id="1389" id="yr_1389">2015</yr>;<v title="Volume" apt_id="1390" id="v_1390">348</v>:<pages title="Pages" apt_id="1391" id="pages_1391">880–6</pages>.</jcit></bib><bib type="arabic" id="bib_1392" sno="53" suffix="." apt_id="1392"><jcit apt_id="1393" id="jcit_1393"><au apt_id="1394" id="au_1394"><s title="Surname" apt_id="1395" id="s_1395">Doherty</s><f title="First name" apt_id="1396" id="f_1396">EE</f></au>, <au apt_id="1397" id="au_1397"><s title="Surname" apt_id="1398" id="s_1398">Karki</s><f title="First name" apt_id="1399" id="f_1399">A</f></au>, <au apt_id="1400" id="au_1400"><s title="Surname" apt_id="1401" id="s_1401">Wilcox</s><f title="First name" apt_id="1402" id="f_1402">XE</f></au>, <etal title="etal" apt_id="1403" id="etal_1403">et al.</etal> <at title="Article Title" apt_id="1404" id="at_1404">ADAR activation by inducing a syn conformation at guanosine adjacent to an editing site</at>. <pt title="Periodical Title" apt_id="1405" id="pt_1405">Nucleic Acids Res</pt> <yr title="Year" apt_id="1406" id="yr_1406">2022</yr>;<v title="Volume" apt_id="1407" id="v_1407">50</v>:<pages title="Pages" apt_id="1408" id="pages_1408">10857–68</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/nar/gkac897" apt_id="1409" id="url_1409">https://doi.org/10.1093/nar/gkac897</url> </jcit></bib><bib type="arabic" id="bib_1410" sno="54" suffix="." apt_id="1410"><jcit apt_id="1411" id="jcit_1411"><au apt_id="1412" id="au_1412"><s title="Surname" apt_id="1413" id="s_1413">Reautschnig</s><f title="First name" apt_id="1414" id="f_1414">P</f></au>, <au apt_id="1415" id="au_1415"><s title="Surname" apt_id="1416" id="s_1416">Fruhner</s><f title="First name" apt_id="1417" id="f_1417">C</f></au>, <au apt_id="1418" id="au_1418"><s title="Surname" apt_id="1419" id="s_1419">Wahn</s><f title="First name" apt_id="1420" id="f_1420">N</f></au>, <etal title="etal" apt_id="1421" id="etal_1421">et al.</etal> <at title="Article Title" apt_id="1422" id="at_1422">Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA</at>. <pt title="Periodical Title" apt_id="1423" id="pt_1423">Nat Biotechnol</pt> <yr title="Year" apt_id="1424" id="yr_1424">2024</yr>;<url title="URL" type="uri" href="https://doi.org/10.1038/s41587-024-02313-0" apt_id="1425" id="url_1425">https://doi.org/10.1038/s41587-024-02313-0</url> <query><button type="button" title="Copy Editor to Author-AU: Volume and Pages are missing in this reference [54]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="28" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">28</span></button></query></jcit></bib></ref></bm></doc>